



Study Protocol

P4-C2-006

DARWIN EU[®] – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

Authors: Xintong Li, Edward Burn, Kim Lopez-Guell

23/07/2025

Version 3.0

Public

Contents

LIST OF ABBREVIATIONS.....	5
1. TITLE	6
2. DESCRIPTION OF THE STUDY TEAM	6
3. ABSTRACT	8
4. AMENDMENTS AND UPDATES.....	10
5. MILESTONES.....	11
6. RATIONALE AND BACKGROUND	11
7. RESEARCH QUESTION AND OBJECTIVES	11
8. RESEARCH METHODS.....	12
8.1 Study type and study design.....	12
8.2 Study setting and data sources.....	12
Table 1. Description of the selected data sources.	13
8.3 Study period.....	15
8.4 Follow-up	15
Table 2. Operational Definition of Time 0 (index date) and other primary time anchors.	16
8.5 Study population with inclusion and exclusion criteria.....	17
Table 3. Operational Definitions of Inclusion Criteria.	18
Table 4. Operational Definitions of Exclusion Criteria.	19
8.6 Variables	20
8.6.1. Exposure/s	20
Table 5. Operational Definitions of Exposure.	21
8.6.2 Outcome/s	22
8.6.3 Other covariates, including confounders, effect modifiers and other variables (where relevant).....	22
Table 6. Operational Definitions of Covariates.	23
8.7 Study size	24
8.8 Analysis	24
8.8.1 Federated network analyses.....	24
8.8.2 Patient privacy protection	24
8.8.3 Diagnostics of drug exposure information on database	24
8.8.4 Construction of treatment episodes and sequence.....	24
8.8.5 Statistical analysis plan	25
Objective 1: Prevalence.....	25
Objective 2: Incidence	25
Objective 3: Indication and characteristics	25
Objective 4: Initial dose, cumulative dose, treatment duration, and number of prescriptions	26
Objective 5: Total treatment duration	26
Objective 6: treatment pathway	26
Figure 3. Parameters in TreatmentPatterns package.	27
8.8.6 Sensitivity analysis	28
Table 7. Sensitivity analyses – rationale, strengths, and limitations.....	28
8.8.7 Output.....	28
8.9 Evidence synthesis	28
9. DATA MANAGEMENT	28

10.	QUALITY CONTROL.....	29
11.	LIMITATIONS OF THE RESEARCH METHODS.....	29
12.	MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS	30
13.	GOVERNANCE BOARD ASPECTS	30
14.	PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS	30
15.	REFERENCES.....	31
16.	ANNEXES	32
	ANNEX I. Code lists for medications and conditions	32
	Annex II. ENCePP checklist for study protocols.....	86

Study Title	DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications
Protocol version	V3.0
Date	23/07/2025
EUPAS register number¹	EUPAS1000000678
Active substance	Lisdexamfetamine (ATC code: N06BA12) Methylphenidate (N06BA04) Atomoxetine (N06BA09) Dexamphetamine (N06BA02) Guanfacine (C02AC02)
Medicinal product	n/a
Objectives	<p>The overall aim of this study is to characterise the use of ADHD medications in the period of 2010 to 2024. The specific objectives are:</p> <ol style="list-style-type: none"> 1. To estimate the monthly and yearly period prevalence of use of each ADHD medicine, overall and stratified by age and sex in each database. 2. To estimate the monthly, and yearly incidence of use of each ADHD medicine, overall and stratified by age and sex in each database. 3. Among incident users of each ADHD medicine, to identify the indication at the time of the initial prescribing/dispensing, overall and stratified by age and sex. 4. Among incident users of each ADHD medicine, to estimate the initial dose, cumulative dose, and time on treatment of the initial medication, overall and stratified by age, sex, and indication at index. 5. Among new users of any ADHD medicine, to estimate the total treatment duration, number of prescriptions overall and by medicine, stratified by initial medicine, age, and sex. 6. To identify the treatment pathway of each individual who initiated an ADHD medicine, including treatment add-on, switch, and concurrent medication/co-prescribing, stratify by calendar time of initiation, age, and sex.
Countries of study	Denmark, Germany, Norway, Spain, and Sweden.
Author	<p>Xintong Li x.li@darwin-eu.org</p> <p>Edward Burn e.burn@darwin-eu.org</p> <p>Kim Lopez-Guell k.lopezguell@darwin-eu.org</p>

¹This is a routinely repeated study from P3-C1-004 with [EUPAS1000000219](https://eupas1000000219)

LIST OF ABBREVIATIONS

ADHD	Attention deficit hyperactivity disorder
AEMPS	Agencia Española de Medicamentos y Productos Sanitarios
ATC	Anatomical Therapeutic Chemical
BIFAP	Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)
CDM	Common Data Model
COPD	Chronic obstructive pulmonary disease
DARWIN EU®	Data Analysis and Real World Interrogation Network
DK-DHR	Danish Data Health Registries
DUS	Drug Utilization Study
EEA	European Economic Area
EHR	Electronic Health Records
EMA	European Medicines Agency
EU	European Union
GP	General Practitioner
HI-SPEED	Health Impact - Swedish Population Evidence Enabling Data-linkage
SMPA-GU	Swedish Medicines and Products Agency- University of Gothenburg
ICD	International classification of disease
ICD-10-CM	the International Classification of Diseases, Tenth Revision, Clinical Modification
InGef RDB	Institut für angewandte Gesundheitsforschung Berlin GmbH Research Database
IQR	Interquartile range
NLHR	Norwegian Linked Health Registries
OMOP	Observational Medical Outcomes Partnership
PPC	Proportion of patients covered
SIDIAP	Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària
SPOC	Shortages Single Point of Contact

1. TITLE

DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

2. DESCRIPTION OF THE STUDY TEAM

Study team role	Names	Organisation
Principal Investigator	Xintong Li	University of Oxford
Data Scientists	Kim Lopez-Guell Edward Burn	University of Oxford University of Oxford
Epidemiologist	Xintong Li	University of Oxford
Clinical Domain Expert	Daniel Prieto Alhambra	University of Oxford/ Erasmus MC
Study Manager	Natasha Yefimenko	Erasmus MC
Data Partner*	Names	Organisation
DK-DHR	Elvira Bräuner Susanne Bruun Claus Møldrup	Danish Medicines Agency (DKMA)
InGef RDB	Raeleesha Norris Annika Vivirito Alexander Harms Josephine Jacob	Institut für angewandte Gesundheitsforschung Berlin GmbH
NLHR	Hedvig Nordeng Nhung Trinh Saeed Hayati	Universitetet i Oslo
BIFAP	Miguel-Ángel MACIÁ- MARTÍNEZ Martín Pérez, María del Mar Martínez-Alcalá García, Hermenegildo Carlos Llorente Garcia, Ana Redondo Álvarez, Emma Macia Martinez, Miguel Angel	Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
SIDIAP	Anna Palomar Cros Elena Roel Herranz Agustina Giuliadori Picco Irene López Sánchez	IDIAP JGoI
HI-SPEED	Huiqi Li Fredrik Nyberg	Swedish Medicines and Products Agency- University of Gothenburg (SMPA-GU)

	Nicklas Pihlström Rickard Ljung	
--	------------------------------------	--

*Data partners' role is to execute code at their data source, review and approve their results. They do not have an investigator role. Data analysts/programmers do not have an investigator role and thus declaration of interests (DOI) for them is not needed.

3. ABSTRACT

Title

DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

Rationale and background

A first study has been performed in 2024 at the request of the SPOC Working Party (responsible for monitoring and reporting events that could affect the supply of medicines in the EU). Monitoring possible shortages of different medicines to treat Attention-Deficit Hyperactivity Disorder (ADHD) is critical mainly due to an increased demand in multiple markets, production constraints related to raw material availability, new regulatory approvals for some medicines, and changes in the competitive landscape. The main products under monitoring are lisdexamfetamine and methylphenidate, but three more have the indication in Europe (atomoxetine, dexamphetamine, and guanfacine). Currently, the situation has improved slightly in the EU and there are no critical shortages. However, it is anticipated that constraints in the supply may continue. The initial study was conducted to better anticipate potential shortages and its impact on appropriate patient management, as it is important to assess the evolution of prescriptions over time and get an overview of how these ADHD medicines are used across Europe. The Spanish Regulatory Authority (AEMPS), after having seen the results of the initial study, has asked the EMA if we could repeat the study with additional data partners, especially the Spanish ones, as only one Spanish data partner was finally included in the first study, as reported (https://catalogues.ema.europa.eu/system/files/2025-03/DARWIN%20EU_Report_P3-C1-004_ADHD_V5.pdf).

Research question and objectives

The overall aim of this study is to characterise the use of ADHD medications in the period of 2010 to 2023. The specific objectives are:

1. To estimate the monthly and yearly period prevalence of use of each ADHD medicine, overall and stratified by age and sex in each database.
2. To estimate the monthly and yearly incidence of use of each ADHD medicine, overall and stratified by age and sex in each database.
3. Among incident users of each ADHD medicine, to identify the indication at the time of the initial prescribing/dispensing, overall and stratified by age and sex.
4. Among incident users of each ADHD medicine, to estimate the initial dose, cumulative dose, and time on treatment of the initial medication, overall and stratified by age and sex.
5. Among new users of any ADHD medicine, to estimate the total treatment duration, number of prescriptions overall and by medicine, stratified by initial medicine, age, and sex.
6. To identify the treatment pathway of each individual who initiated an ADHD medicine, including treatment add-on, switch, and concurrent medication/co-prescribing, stratify by calendar time of initiation, age, and sex.

Methods

Study design

Population-level drug utilisation study (Objectives 1 and 2)

Patient-level utilisation study (Objectives 3 - 6, new user cohort study).

Population

In the population-level utilisation of ADHD medications (Objectives 1 and 2, prevalence, incidence), all people aged 3 years and older, registered in the respective databases since 1st of January of 2010 to the latest available data, with at least 365 days of prior data availability, will be included.

In the patient-level utilisation of ADHD medications (Objectives 3 and 4), incident users will be identified using the first record of any of the ADHD medications of interest within the study period, having no previous records for the same medication during the 12 months before cohort entry.

In the patient-level utilisation of ADHD medications (Objectives 5 and 6), new users will be identified using the first record of any of the ADHD medications of interest within the study period, with no previous records of any study medications any time before entry.

Variables

Drugs of interest: Five approved medications for the treatment of ADHD in Europe: methylphenidate, dexamphetamine, lisdexamfetamine, atomoxetine, and guanfacine.

Data source

1. Denmark: Danish Data Health Registries (DK-DHR)
2. Germany: InGef Research Database (InGef RDB)
3. Norway: Norwegian Linked Health Registry data (NLHR)
4. Spain: Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (BIFAP)
5. Spain: The Information System for Research on Primary Care (SIDIAP)
6. Sweden: Health Impact - Swedish Population Evidence Enabling Data-linkage (HI-SPEED)

Statistical analysis

Objectives 1 to 2 are population-level drug utilisation study, monthly and yearly period prevalence, and incidence use of each ADHD medications will be estimated, overall and stratified by age group and sex.

Objectives 3 to 6 are patient-level drug utilisation study. In Objectives 3 and 4, incident user cohorts will be constructed for each ADHD medicine with a pre-defined washout period, characteristics of the user will be described, indication for the initial prescribing/dispensing will be estimated, overall and stratified by age and sex. Initial dose, cumulative dose, and length of the treatment will be calculated. In Objectives 5 and 6, we will construct new user cohorts of any ADHD medicine, estimate the total treatment duration and number of prescriptions. Treatment pathways will be defined and proportion of individuals in each path and the length of each treatment stage will be reported.

For all analyses, a minimum cell counts of 5 will be used when reporting results, with any smaller counts will be noted as "<5".

4. AMENDMENTS AND UPDATES

Number	Date	Section of Study Protocol	Amendment or Update	Reason
1.0	13/06/2025	n/a	Update from initial study protocol (P3-C1-004 study, EUPAS1000000219)	This is a routinely repeated study built on the protocol of the initial study (P3-C1-004)

Comparison with previous protocols

This is a routinely repeated study from the P3-C1-004 study. The P3-C1-004 study was registered in the HMA/EMA RWD catalogue (<https://catalogues.ema.europa.eu/node/4121/data-management>) with the EU PAS register number EUPAS1000000219. The study code from P3-C1-004 is available in the GitHub repository: <https://github.com/darwin-eu-studies/P3-C1-004-ADHD-DUS/tree/main>.

The following updates are the changes included in the routinely repeated analysis P4-C2-006 when compared with P3-C1-004:

Sections	P3-C1-004 study (previous OTS)	P4-C2-006 study (current study)
Data Partners	<ul style="list-style-type: none"> • CPRD • IPCI • IQVIA DA Germany • IQVIA LPD Belgium • SIDIAP • BIFAP 	<ul style="list-style-type: none"> • DK-DHR • InGef RDB • NLHR • BIFAP • SIDIAP • HI-SPEED
Reference study protocol	n/a	P3-C1-004 (EUPAS1000000219)
Changes from reference study protocol	<ul style="list-style-type: none"> • Calendar time: Analysis was stratified by calendar time included month, quarter, and year in objectives 2-4. • Age groups: 3-11, 12-17, 18-24, ≥25 years • Characteristics of new users: comorbidities and medication use any time prior to index. • Indications: ADHD, narcolepsy, eating disorders, fatigue, major depression disorder, apathy, mood disorders (exclude major depressive disorder), cognitive dysfunction (exclude dementia), dementia, treatment of addictions, behavioural disorders (exclude ADHD), autism, intellectual disability, post-traumatic brain injury • Objective 4: drug utilisation on dose and duration 	<ul style="list-style-type: none"> • Calendar time: Stratification by calendar time will include month and year in objectives 2-4. • Age groups: we will add the group of 3-5 years old. • Characteristics of new users: comorbidities any time prior to index, medication use in the year prior. In addition, we will describe use of other ADHD medication prior to index. • Indications: add hypertension disorder to the list of potential indications • Objective 4: we will also report the restart or switching after discontinuation of the first treatment episode.

5. MILESTONES

STUDY DELIVERABLES	TIMELINE
Final Study Protocol	July 2025
Creation of Analytical code	August 2025
Execution of Analytical Code on the data	September 2025
Draft Study Report	October 2025
Final Study Report	November 2025

6. RATIONALE AND BACKGROUND

A first study ([EUPAS1000000219](#)) has been performed in 2024 at the request of the SPOC Working Party (responsible for monitoring and reporting events that could affect the supply of medicines in the EU). Monitoring possible shortages of different medicines to treat Attention-Deficit Hyperactivity Disorder (ADHD) is critical, mainly due to an increased demand in multiple markets, production constraints related to raw material availability, new regulatory approvals for some medicines, and changes in the competitive landscape. The main products under monitoring are lisdexamfetamine and methylphenidate, but three more have the indication in Europe (atomoxetine, dexamphetamine, and guanfacine). Currently, the situation has improved slightly in the EU and there are no critical shortages. However, it is anticipated that constraints in the supply may continue.

The initial study was conducted to better anticipate potential shortages and its impact on appropriate patient management, as it is important to assess the evolution of prescriptions over time and get an overview of how these ADHD medicines are used across Europe.

The Spanish Regulatory Authority (AEMPS), after having seen the results of the initial study, has asked the EMA if we could repeat the study with additional data partners, especially the Spanish ones, as only one Spanish data partner was finally included in the first study, as reported (https://catalogues.ema.europa.eu/system/files/2025-03/DARWIN%20EU_Report_P3-C1-004_ADHD_V5.pdf). This study is now being repeated to include additional data sources with more recent data. In addition, since all ADHD medications are approved only for individuals aged six and older, their use in children under six years of age is considered off-label. Therefore, in the current study, we will add a stratum of young child aged below five years old to assess potential off-label use of these medications.

7. RESEARCH QUESTION AND OBJECTIVES

The overall aim of this study is to characterise the use of ADHD medications in the period of 2010 to 2024. The specific objectives are:

1. To estimate the monthly and yearly period prevalence of use of each ADHD medicine, overall and stratified by age and sex in each database.
2. To estimate the monthly, and yearly incidence of use of each ADHD medicine, overall and stratified by age and sex in each database.
3. Among incident users of each ADHD medicine, to identify the indication at the time of the initial prescribing/dispensing, overall and stratified by age and sex.
4. Among incident users of each ADHD medicine, to estimate the initial dose, cumulative dose, and time on treatment of the initial medication, overall and stratified by age and sex.

5. Among new users of any ADHD medicine, to estimate the total treatment duration, number of prescriptions overall and by medicine, stratified by initial medicine.
6. To identify the treatment pathway of each individual who initiated an ADHD medicine, including treatment add-on, switch, and concurrent medication/co-prescribing, stratified by calendar year of initiation, age group, and sex.

8. RESEARCH METHODS

8.1 Study type and study design

Cohort studies will be conducted using routinely collected health data from six databases. The study will comprise two consecutive parts:

1. Population-level cohort study will be conducted to address objectives 1 and 2, where prevalence and incidence of ADHD medications will be estimated.
2. New drug user cohort design will be used for objectives 3 to 6, where new users of ADHD medications will be identified and followed up.

8.2 Study setting and data sources

This study will be conducted using routinely collected data from six databases in 5 European countries. All databases were previously mapped to the OMOP CDM.

Data sources

1. Denmark: Danish Data Health Registries (DK-DHR)
2. Germany: InGef Research Database (InGef RDB)
3. Norway: Norwegian Linked Health Registry data (NLHR)
4. Spain: Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (BIFAP)
5. Spain: The Information System for Research on Primary Care (SIDIAP)
6. Sweden: Health Impact - Swedish Population Evidence Enabling Data-linkage (HI-SPEED)

Rationale for database selection

The selection of databases for this study was performed based on the relevance for the proposed research question among those databases onboarded and available within DARWIN EU® at the time of the study feasibility assessment, as well as operational considerations knowing the timing of the study and the expansion of the initial study to additional fit-for-use data partners.

Medications for ADHD are primarily prescribed and managed in primary care settings in Europe. To estimate the population-level and patient-level drug utilisation study, population-based databases are needed. The population-based databases will enable us to properly define the denominator for the calculation of incidence and prevalence. All the six selected databases are population-level primary care records including prescription information of medications, which will allow the identification of new treatment episodes.

Two databases from Spain (BIFAP and SIDIAP) will be included in this study to increase the geographic coverage of the study population as the two databases are not covering the same regions.

The three linked national registries from Scandinavian countries included should have relevant sample size and provided nationwide prevalence/ incidence data (DK-DHR, NLHR, HI-SPEED).

Table 1. Description of the selected data sources.

Country	Name of Database	Justification for Inclusion	Health Care setting	Type of Data	Number of active subjects*	Feasibility counts of exposure	Data lock for the last update
Denmark	DK-DHR	Linked national registries from Denmark	Primary and secondary	Registries	5.91M	methylphenidate: 208500 lisdexamfetamine: 62800 dextroamphetamine: 9700 atomoxetine: 67700 guanfacine: 5200	08-01-2025
Germany	InGef RDB	Nation wide claims data with primary and secondary care from Germany	Primary and secondary	Claims	7.64M	methylphenidate: 23500 lisdexamfetamine: 28600 dextroamphetamine: 2200 atomoxetine: 1500 guanfacine: 4200	01-04-2025
Norway	NLHR	Linked national registries from Norway	Primary and secondary	Registries	6.89M	methylphenidate: 109100 lisdexamfetamine: 58400 dextroamphetamine: 11600 atomoxetine: 16200 guanfacine: 2600	29-10-2024
Spain	BIFAP	Covers primary and secondary care setting where ADHD medication prescriptions are issued	Primary Care, secondary care	EHR	16.9 million	methylphenidate: 148800 lisdexamfetamine: 27500 atomoxetine: 20200 guanfacine: 7900	31-12-2024
Spain	SIDIAP	Covers primary and secondary care setting where ADHD medication prescriptions are issued	Primary Care, secondary care	EHR	5.94 M	methylphenidate: 72300 lisdexamfetamine: 8800 atomoxetine: 9500	30-06-2023

Country	Name of Database	Justification for Inclusion	Health Care setting	Type of Data	Number of active subjects*	Feasibility counts of exposure	Data lock for the last update
						guanfacine: 3300	
Sweden	HI-SPEED	linked national registries from Sweden	Primary and secondary	Registries	10.5M	methylphenidate: 260700 lisdexamfetamine: 188600 dextroamphetamine: 34500 atomoxetine: 55000 guanfacine: 41400	10-09-2024

DK-DHR = Danish Data Health Registries, InGef RDB = Institut für angewandte Gesundheitsforschung Berlin GmbH Research Database, NLHR = Norwegian Linked Health Registries, BIFAP = Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público, SIDIAP = Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària, HI-SPEED = Health Impact - Swedish Population Evidence Enabling Data-linkage

*Number of active subjects are estimated by number of patients under observation as on 1st January 2023.

8.3 Study period

The study period will start on 1st January 2010 to the latest data availability of each participated database.

8.4 Follow-up

In the analysis of population-level DUS (Objectives 1 and 2), a denominator population will be constructed using all eligible people in the database. Individuals will begin contributing person time on the respective date of the latest of the following: 1) study start date, 2) date at which the 365 days data availability reached, and 3) age 3 years old.

Subjects will stop contributing person time at the earliest date of the following: 1) end of available data in each of the data sources or 2) date at which the observation period of the specific person ends.

In the patient-level DUS analysis (Objective 3 to 6), new users of ADHD medications will be followed from the date of the new incident prescription to the earliest date of the following: 1) the last medication record of ADHD medication, 2) end of available data in each of the data sources, or 3) date at which the observation period of the specific person ends.

Table 2. Operational definition of time 0 (index date) and other primary time anchors.

Study population name(s)	Time Anchor Description (e.g. time 0)	Number of entries	Type of entry	Washout window	Care Setting ¹	Code Type	Diagnos is position	Incident with respect to...	Measure ment characteri stics/ validation	Source of algorit hm
General population (described in 8.5 Study Population with inclusion and exclusion criteria)	The latest of the following: 1) study start date 2) date at which the 365 days data availability reached, and 3) age 3 years old	Multiple		n/a	n/a	n/a	n/a	n/a	n/a	n/a
Incident user cohort, drug substance level (objectives 3 and 4)	Incident use of a specific medication within study period of 2010 to 2024, defined using 365 days washout window.	Multiple	Incident	[-365, -1]	OP	RxNor m / ATC	n/a	Prior use of ADHD medication	n/a	n/a
New user cohort of any ADHD medications (objectives 5 and 6)	First prescription of any ADHD medicine within study period of 2010 to 2024 with no previous use of any study medication	Single	Incident	[-Inf, -1]	OP	RxNor m / ATC	n/a	Prior use of any ADHD medication	n/a	n/a

¹ IP = inpatient, OP = outpatient, ED = emergency department, OT = other, n/a = not applicable

8.5 Study population with inclusion and exclusion criteria

Population-level utilisation of ADHD medications: general population

All people aged 3 years and older [1], registered in the respective databases since the 1st of January of 2010 to the latest available data, with at least 365 days of prior data availability, will participate in the population-level analysis of period prevalence and incidence of ADHD medications of interest.

Patient-level utilisation of ADHD medications: new user cohort

In objectives 3 and 4, incident user cohorts of any ADHD medication, as well as each ADHD medication, will be created, using a 365-day washout window.

Therefore, the “incident use of any ADHD medication” refers to a prescription/dispensation of any ADHD medication during the study period and without use of any ADHD medication in the previous year. An individual can enter the cohort multiple times if the inclusion/ exclusion criteria are met.

The “incident use of individual medication” refers to a prescription/dispensation of a specific ADHD medication during the study period and without use of respective medication in the previous year. For example, if an individual started methylphenidate, then switched to atomoxetine, the individual could contribute to the new user cohorts of both methylphenidate and atomoxetine.

In each database, six incident user cohorts of the medications licensed for ADHD treatment will be constructed separately: any ADHD medication, dexamphetamine, lisdexamfetamine, methylphenidate, atomoxetine, and guanfacine.

In objectives 5 and 6, new users will be identified using the first record of any of the ADHD medications of interest within the study period, having no previous records for any study medication any time prior to entry (e.g. individual who received their first ever medication during study period). The index date will be defined as the date of the first eligible medication record.

We will exclude individuals with missing data on sex or age.

Table 3. Operational definitions of inclusion criteria.

Criterion	Details	Order of application	Assessment window	Care Settings	Code Type	Diagnosis position	Applied to study populations :	Measurement characteristics / validation	Source for algorithm
In observation	All individuals present in the period 2010 to the latest available data	n/a		n/a	n/a	n/a	General population	n/a	n/a
Age >= 3	Individual will not contribute to person-time before 3 years old	Prior		n/a	n/a	n/a	General population	n/a	n/a
Prior data availability	Study participants will be required to have 365 days prior history observed before contributing observation time	Prior	[-365,0]	n/a	n/a	n/a	General population	n/a	n/a
Washout period for incident users of individual medication	Having no previous records for the same study medication during the 365 days before cohort entry	Prior	[-365, -1]	OP	RxNorm	n/a	New user cohort, drug substance level	n/a	n/a
Washout period for new users of any medication	Having no previous records of any study medication before entry	Prior	[-Inf, -1]	OP	RxNorm	n/a	New user cohort, any study medication	n/a	n/a

n/a = not applicable

Table 4. Operational definitions of exclusion criteria.

Criterion	Details	Order of application	Assessment window	Care Settings	Code Type	Diagnosis position	Applied to study populations:	Measurement characteristics/ validation	Source for algorithm
Missing data	Exclude individuals with missing data on sex or age.	Before	n/a	n/a	n/a	n/a	General population, new user cohort	n/a	n/a

n/a = not applicable

8.6 Variables

8.6.1. Exposure/s

Medication	Class	ATC code	Approved indication	Time of approval by EMA
Dexamphetamine	Stimulants	N06BA02	ADHD ≥ 6 years; Narcolepsy	
Lisdexamfetamine	Stimulants	N06BA12	ADHD ≥ 6 years; Binge eating disorder (FDA)	2012
Methylphenidate	Stimulants	N06BA04	ADHD ≥ 6 years; Narcolepsy	
Atomoxetine	Non-stimulants	N06BA09	ADHD ≥ 6 years	2004-2005 (children and adolescents) 2013 (adults)
Guanfacine	Non-stimulants	C02AC02	ADHD 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective; Hypertension	2015

Table 5. Operational definitions of exposure.

Exposure group name(s)	Details	Washout window	Assessment Window	Care Setting ¹	Code Type	Diagnosis position	Applied to study populations	Incident with respect to...
ADHD medications use	Prescription/ dispensation of medication, for estimating prevalence		n/a	OP		n/a	General population	
Incident use of any ADHD medication	Have no use of any ADHD medication in the year before	[-365, -1]	n/a	OP		n/a	People used ADHD medication	Previous use
Incident use of individual ADHD medication	Have no use of the specific medication in the year before	[-365, -1]	n/a	OP		n/a		Previous use
New use to any ADHD medication	Have no use of any ADHD medication any time before	[-Inf, -1]	n/a	OP		n/a		Previous use

¹ IP = inpatient, OP = outpatient, n/a = not applicable

8.6.2 Outcome/s

No outcome variable will be included in this study.

8.6.3 Other covariates, including confounders, effect modifiers and other variables (where relevant)

Population-level drug utilisation study (incidence and prevalence)

- Calendar time: Month, year
- Age groups:
 - Overall (3+ years old), children (aged 3–11 years), adolescents (12–17 years), young adults (18–24 years), and adults (≥25 years). [2]
 - Age wider group: children (aged 3–17 years) and adults (≥ 18 years).
 - Additional age group of young children to inspect off-label use (aged 3-5 years)
- Sex: Both, female, male

Patient-level drug utilisation study

Pre-specified conditions that are the potential indication of ADHD medications, including both authorised and non-authorised indications (Objective 3):

- Authorised indications:
 - ADHD
 - Narcolepsy (Authorised for methylphenidate and dexamphetamine only)
 - Hypertension disorder (Authorised for guanfacine only)
- Potential off-label conditions [3,4]:
 - Eating disorders
 - Fatigue
 - Major depression disorder
 - Apathy
 - Mood disorders (exclude major depressive disorder)
 - Cognitive dysfunction (exclude dementia)
 - Dementia
 - Treatment of addictions
 - Behavioural disorders (exclude ADHD)
 - Autism
 - Intellectual disability
 - Post-traumatic brain injury

The conditions will be defined by concept set. A crude list of OMOP concept IDs for ADHD and narcolepsy are available in the annex table. Concept sets for these conditions are listed in the annex.

Table 6. Operational definitions of covariates.

Characteristic	Details	Type of variable	Assessment window	Care Settings ¹	Code Type	Diagnosis Position ²	Applied to study populations
Indication conditions	To assess the potential indication of study medication	Binary	[-7,0] [-30,0] [-90,0] [-Inf,0]	OP, IP	SNOMED	n/a	New user cohorts

¹ IP = inpatient, OP = outpatient, n/a = not applicable

² Specify whether a diagnosis code is required to be in the primary position (main reason for encounter)

8.7 Study size

No formal sample size has been estimated for this study. However, based on the feasibility assessment performed before the initiation of the study, the expected total number of users of each ADHD medication of interest will be the following across all databases:

- methylphenidate: DK-DHR: 208500, InGef RDB: 23500, NLHR: 109100, BIFAP: 148800, SIDIAP: 72300, HI-SPEED: 260700
- lisdexamfetamine: DK-DHR: 62800, InGef RDB: 28600, NLHR: 58400, BIFAP: 27500, SIDIAP: 8800, HI-SPEED: 188600
- dextroamphetamine: DK-DHR: 9700, InGef RDB: 2200, NLHR: 11600, HI-SPEED: 34500
- atomoxetine: DK-DHR: 67700, InGef RDB: 1500, NLHR: 16200, BIFAP: 20200, SIDIAP: 9500, HI-SPEED: 55000
- guanfacine: DK-DHR: 5200, InGef RDB: 4200, NLHR: 2600, BIFAP: 7900, SIDIAP: 3300, HI-SPEED: 41400

These numbers were estimated based on the number of unique patients with a target medication recorded, without applying any inclusion or exclusion criteria, and were not limited to the study period. Dextroamphetamine is not available in BIFAP and SIDIAP.

8.8 Analysis

8.8.1 Federated network analyses

Analyses will be conducted separately for each database. Before study initiation, test runs of the analytics are performed on a subset of the data sources or on a simulated set of patients, and quality control checks are performed. Once all the tests are passed, the final package is released in the version-controlled Study Repository for execution against all the participating data sources.

The data partners locally execute the analytics against the OMOP-CDM in R Studio and review and approve the by-default aggregated results before returning them to the Coordination Centre. Sometimes multiple execution iterations are performed, and additional fine tuning of the code base is needed. A service desk will be available during the study execution for support.

The study results of all data sources are checked after which they are made available to the team in the Digital Research Environment and the Dissemination Phase can start. All results are locked and timestamped for reproducibility and transparency.

8.8.2 Patient privacy protection

To prevent confidentiality issues, cell counts lower than 5 will be reported as “<5”.

8.8.3 Diagnostics of drug exposure information on database

Before executing the study code, we will use the DrugExposureDiagnostics R Package (<https://darwin-eu.github.io/DrugExposureDiagnostics>) to summarise the ingredient specific drug exposure data of each database. The results from the diagnostics will provide detailed information related to drug dose, form, and days of supply, which will inform us whether a database have sufficient information for the patient level DUS analysis.

8.8.4 Construction of treatment episodes and sequence

Medication record and treatment episode: In the OMOP CDM data, ADHD medications will be recorded in the “drug_exposure” table. Each row of the data represents a prescription/dispensing and comprises of a start date (e.g. a start date of a prescription, the date a prescription was filled, or the date on which a Drug

administration was recorded) and an end date (if not explicitly available in the source data, inferred from duration of days' supply) of that drug exposure, which allows to estimate the duration of this drug exposure. The start and end date were defined during the ETL process of data mapping and differs between databases, and detailed conventions of these variables are available at:

https://ohdsi.github.io/CommonDataModel/cdm54.html#drug_exposure. To construct the treatment episode of a specific medication, we will first identify the first record of the medication and using the exposure start date as the index date. Subsequent drug exposure records will be combined into continuous treatment episodes using a pre-defined gap of 30 days (grace period, sensitivity analysis will use 90 days as grace period). [5]

8.8.5 Statistical analysis plan

R-packages

The population-level drug utilisation will be calculated based on OMOP-CDM mapped data using the "IncidencePrevalance" R package, developed by DARWIN EU®. The patient-level drug utilisation will be calculated based on OMOP-CDM mapped data using the "DrugUtilisation", "CohortCharacteristics", and "TreatmentPatterns" R packages, developed by DARWIN EU®.

Objective 1: Prevalence

Prevalence will be calculated as monthly and yearly period prevalence, which summarises the total number of users of the drug of interest during a given calendar month/year divided by the population under observation during that month/year. Therefore, period prevalence gives the proportion of users at any time during a specified interval. We will not require the denominator population to be under observation for the entire month/year. Binomial 95% confidence intervals will be calculated.

The analysis will be stratified by age group, sex, and age group by sex (e.g. group of "males aged 3-11 years old").

Objective 2: Incidence

Monthly incidence rates of each ADHD medication of interest will be calculated as the of number of new users per 100,000 person-years of the population at risk of getting exposed during the period for each calendar month (e.g. 1st January – 31st January). Incidence rates will also be calculated yearly. Those study participants who enter the denominator population will then contribute time at risk up to their first use (prescription or dispensation) of study medication during the study period. If they do not have a drug exposure, they will contribute time at risk up as described above in section 8.3 Study period and 8.4 Follow-up. Incidence rates will be given together with 95% Poisson exact confidence intervals.

The analysis will be stratified by age group, sex, and age group by sex.

Objective 3: Indication and characteristics

For the new user cohorts of any ADHD medication or individual medication, we will provide a patient-level characteristics index on cohort entry. Demographic information, common comorbidities (any time prior to index), and common medication use (one year prior to index) will be reported. We will also report the percentage of people who used other ADHD medications (any time prior) to inspect potential off-label use. This is because non-stimulants are recommended as second-line treatment for ADHD.

We will assess the indications of the study medication using four different windows: within 7 days before index, within 30 days, within 90 days, and any time before index. [6,7] Potential indications will be presented as number and percentage of patients with a record of the respective indication. We will report the potential indications as non-mutually exclusive groups, meaning that the percentages of all indications could add up to over one hundred.

In the previous study, we found that the off-label condition for ADHD medication was very rare. Therefore, we will only report all listed potential indications using the 30 days prior window. We then grouped the off-

label conditions together and finally assessed the following indication/indication groups for each medication within the three different time windows:

- Dexamphetamine: ADHD, narcolepsy, and potential off-label conditions as listed in 8.6.3.
- Lisdexamfetamine: ADHD, and potential off-label conditions as listed in 8.6.3.
- Methylphenidate: ADHD, narcolepsy, and potential off-label conditions as listed in 8.6.3.
- Atomoxetine: ADHD, and potential off-label conditions as listed in 8.6.3.
- Guanfacine: ADHD, hypertension, and potential off-label conditions as listed in 8.6.3.

The analysis will be stratified by age group, sex, and age group by sex.

Guanfacine has been approved for treatment of ADHD in those aged 6-17 years old for whom stimulants are not suitable, not tolerated, or have been shown to be ineffective, as well as hypertension. To contextualise the potential off-label use for the guanfacine initiator cohort, we will report the proportion of the following: a.) age 6-17 but has no approved condition of ADHD or hypertension, b.) any use in children under 6 years old and in adults without hypertension, or c.) age 6-17 but has no history of stimulant use.

Objective 4: Initial dose, cumulative dose, treatment duration, and number of prescriptions

Among the new user cohort of each individual ADHD medicine, initial dose and cumulative dose will be assessed at ingredient level for the initial medication. Duration of the treatment episode will be reported. As explained in the previous section, a grace period of 30 days will be used to define the treatment episode. Treatment duration will be summarized providing the minimum, p25, median, p75, and maximum treatment duration. Number of prescriptions within the treatment episode will be reported.

We will assess the restart or switching to another medication after discontinuation of the original medication. We will report the number and percentage of people who restart or switch to another medication within 30 days, 90 days, and 180 days after their first discontinuation. The analysis will be stratified by age group, sex, and age group by sex.

Objective 5: Total treatment duration

For this objective, new users of any ADHD medication will be followed until the last drug record. Total treatment duration will be calculated as the days between the first initiation of any ADHD medication, till the last recorded ADHD medication. Number of prescriptions during this period will be reported as total and at drug substance level.

We will estimate the proportion of patients covered (PPC), which measures the proportion of live patients currently covered by treatment on a given day after treatment initiation. [8] This method has been used to study treatment persistence and is less sensitive to changes in grace periods.

Objective 6: treatment pathway

Individuals who started any ADHD medication will be followed up from the date of first medication of interest to the last record of any study medication.

The treatment pathway will be constructed using the standardised method using the “TreatmentPatterns” R Package [9]. The following figure explains how treatment combination will be defined. The minimum overlap of different treatments to be considered as combination treatment (combinationWindow) is 30 days in the purposed study.




Figure 3. Parameters in TreatmentPatterns package.

The following parameters will be defined in this study. The target cohort refers to the new user cohort of any ADHD medication, whereas the event(s) refer to treatment(s) of interest.

We will use a Sankey diagram to illustrate the treatment pathways. To avoid an overwhelming figure, we will only include treatment pathways representing more than 5% people in the entire cohort. Pathways with less than 5% frequency will not be reported.

Individual pathway settings		
periodPriorToIndex	The period (number of days) prior to the index date of the target cohort from which treatments should be included	0 (not relevant as cohort entry start at treatment initiation)
minEraDuration	Minimum time an event era should last to be included in the analysis	1 day
eraCollapseSize	Maximum gap within two eras of the same event cohort which would still allow the eras to be collapsed into one era	30 days (in line with the grace period)
combinationWindow	Time that two event eras need to overlap to be considered a combination treatment	30 days
minPostCombinationDuration	Minimum time that an event era before or after a generated combination treatment should last to be included in the pathway as a separate treatment	30 days
filterTreatments	Select which treatments should be included in pathway first time occurrences of treatments ('First'), remove sequential repeated treatments ('Changes'), all treatments ('All')	First
maxPathLength	Maximum number of treatments included in pathway	5
Aggregate pathway settings		
groupCombinations	Select to group all non-fixed combinations in one category 'other' in the sunburst plot	TRUE / 10

addNoPaths	Select to include untreated persons without treatment pathway in the sunburst plot	TRUE
------------	--	------

8.8.6 Sensitivity analysis

The ADHD population is known to take drug holidays and temporarily interrupt their treatment, which do not necessarily signify discontinuation of medication use. [10,11] Therefore in the sensitivity analysis, instead of allowing a 30-days gap between drug exposure records, a 90-days gap will be used in constructing treatment episode [12].

Table 7. Sensitivity analyses – rationale, strengths, and limitations.

	What is being varied? How?	Why? (What do you expect to learn?)	Strengths of the sensitivity analysis compared to the primary	Limitations of the sensitivity analysis compared to the primary
Gap between drug exposure	Allow 90 days gap between records of drug exposure.	Patients especially kids may take drug holidays on purpose rather than discontinue	Capture longer treatment period	The treatment episode may not reflect the real drug utilisation

8.8.7 Output

Output will include the following, subject to changes:

Report including an executive summary, and the following table(s) and figure(s).

- Tables 1-6. Characteristics of incident ADHD medication user, one per database.
- Table 7. Potential indication of incident ADHD medication user.
- Table 8. Doses, quantities, and duration of treatment episode.
- Table 9. Number of prescriptions and total time on treatment.
- Figures 1-6. Age-sex specific yearly prevalence of ADHD medication, one per database.
- Figures 7-12. Age-sex specific yearly incidence rates of ADHD medication, one per database.
- Figures 13-17. Sankey diagram of treatment pattern, one per database.

Interactive dashboard will be generated by incorporating all the results (tables and figures) included in the report mentioned above.

8.9 Evidence synthesis

Previous studies have shown that there were large heterogeneity in ADHD medication consumption between different countries.[13,14] Therefore, results from analyses described in Section 8.7 will be presented separately for each database and no meta-analysis of results will be conducted.

9. DATA MANAGEMENT

All databases will have been mapped to the OMOP common data model. This enables the use of standardised analytics and tools across the network since the structure of the data and the terminology system is harmonised. The OMOP CDM is developed and maintained by the Observational Health Data Sciences and Informatics (OHDSI) initiative and is described in detail on the wiki page of the CDM: <https://ohdsi.github.io/CommonDataModel> and in The Book of OHDSI: <http://book.ohdsi.org>. This analytic code for this study will be written in R. Each data partner will execute the study code against their database containing patient-level data and will then return the results set which will only contain aggregated data.

The results from each of the contributing data sites will then be combined in tables and figures for the study report.

10. QUALITY CONTROL

General database quality control

A number of open-source quality control mechanisms for the OMOP CDM have been developed (see Chapter 15 of The Book of OHDSI <http://book.ohdsi.org/DataQuality.html>). In particular, it is expected that data partners will have run the OHDSI Data Quality Dashboard tool (<https://github.com/OHDSI/DataQualityDashboard>). This tool provides numerous checks relating to the conformance, completeness, and plausibility of the mapped data. Conformance focuses on checks that describe the compliance of the representation of data against internal or external formatting, relational, or computational definitions, completeness in the sense of data quality is solely focused on quantifying missingness, or the absence of data, while plausibility seeks to determine the believability or truthfulness of data values. Each of these categories has one or more subcategories and are evaluated in two contexts: validation and verification. Validation relates to how well data align with external benchmarks with expectations derived from known true standards, while verification relates to how well data conform to local knowledge, metadata descriptions, and system assumptions.

Study specific quality control

When defining drug cohorts, non-systemic products will be excluded from the list of included codes summarised on the ingredient level. A pharmacist will review the codes of the ADHD medication of interest.

Before executing the study code, we will use the DrugExposureDiagnostics R Package (<https://darwin-eu.github.io/DrugExposureDiagnostics/>) to summarise the ingredient specific drug exposure data of each database. The results from the diagnostics will provide detailed information related to drug dose, form, and days of supply, which will inform us whether a database have sufficient information for the patient level DUS analysis.

When defining cohorts for indications, a systematic search of possible codes for inclusion will be identified using CodelistGenerator R package (<https://github.com/darwin-eu/CodelistGenerator>). This software allows the user to define a search strategy and using this will then query the vocabulary tables of the OMOP common data model to find potentially relevant codes.

11. LIMITATIONS OF THE RESEARCH METHODS

The study will be informed by routinely collected health care data that were not collected for research purpose. In particular, a recording of a prescription or dispensation does not mean that the patient actually took the drug.

In objective two, where we will estimate the incidence rates of ADHD medications, we will apply a 365-day washout period to define the incidence use of each ADHD medication. Therefore, for each medication, incident users may have used other medication before the initiation of that specific medication (e.g. a switch of treatment). For the incidence rates of any ADHD medication use, we will require people to have no use of any study medication during the 365 days washout window.

In objectives 3 to 4, where we will look at incident use of a specific study medicine at drug substance level, the washout window will also be applied at drug substance level, the use of that medicine could be an add-on treatment, a switch from previous medicine, or a true new user.

The indications of the study medications will be defined using diagnosis code only, no validation of the phenotypes will be conducted. Furthermore, some of the conditions are usually diagnosed by specialist, the data from which may not be available in the included databases. In addition, the recording of events used

for patient characterization and identification of the (potential) indication may vary across databases and recording of indication may be incomplete. Reduced health care access during the pandemic may lead to delay in diagnostics for indication and subsequent prescriptions of study medications. It could also be possible that patient acquired the medications via other methods which were not captured by the existing data.

12. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE REACTIONS

Adverse events/adverse reactions will not be collected or analysed as part of this evaluation. The nature of this non-interventional study, through the use of secondary data, does not fulfil the criteria for reporting adverse events, according to module VI, VI.C.1.2.1.2 of the Good Pharmacovigilance Practices (https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf).

Only in case of prospective data collection, there is a need to describe the procedures for the collection, management and reporting of individual cases of adverse events/adverse reactions.

13. GOVERNANCE BOARD ASPECTS

Timeline for the ethical application to be confirmed.

14. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS

A PDF report including an executive summary, and the specified tables and/or figures will be submitted to EMA by the DARWIN EU® CC upon completion of the study.

An interactive dashboard incorporating all the results (tables and figures) will be provided alongside the pdf report. The full set of underlying aggregated data used in the dashboard will also be made available if requested.

15. REFERENCES

- 1 Rocco I, Corso B, Bonati M, *et al.* Time of onset and/or diagnosis of ADHD in European children: a systematic review. *BMC Psychiatry*. 2021;21:575.
- 2 Brikell I, Yao H, Li L, *et al.* ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases. *Lancet Psychiatry*. 2024;11:16–26.
- 3 Verghese C, Abdijadid S. *Methylphenidate*. StatPearls Publishing 2023.
- 4 Dadashova R, Silverstone PH. Off-label use of atomoxetine in adults: is it safe? *Ment Illn*. 2012;4:96–101.
- 5 Raman SR, Marshall SW, Gaynes BN, *et al.* An observational study of pharmacological treatment in primary care of children with ADHD in the United Kingdom. *Psychiatr Serv*. 2015;66:617–24.
- 6 Khan MU, Aslani P. A review of measures used to examine medication adherence in people with ADHD at initiation, implementation and discontinuation of pharmacotherapy. *Res Social Adm Pharm*. 2020;16:277–89.
- 7 Li L, Zhu N, Zhang L, *et al.* ADHD pharmacotherapy and mortality in individuals with ADHD. *JAMA*. 2024;331:850.
- 8 Rasmussen L, Pratt N, Hansen MR, *et al.* Using the “proportion of patients covered” and the Kaplan-Meier survival analysis to describe treatment persistence. *Pharmacoepidemiol Drug Saf*. 2018;27:867–71.
- 9 Markus AF, Verhamme KMC, Kors JA, *et al.* TreatmentPatterns: An R package to facilitate the standardized development and analysis of treatment patterns across disease domains. *Comput Methods Programs Biomed*. 2022;225:107081.
- 10 Ibrahim K, Donyai P. Drug holidays from ADHD medication: International experience over the past four decades. *J Atten Disord*. 2015;19:551–68.
- 11 Faraone SV, Spencer TJ, Montano CB, *et al.* Attention-deficit/hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. *Arch Intern Med*. 2004;164:1221–6.
- 12 McCarthy S, Asherson P, Coghill D, *et al.* Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. *Br J Psychiatry*. 2009;194:273–7.
- 13 Chan AYL, Ma T-T, Lau WCY, *et al.* Attention-deficit/hyperactivity disorder medication consumption in 64 countries and regions from 2015 to 2019: a longitudinal study. *EClinicalMedicine*. 2023;58:101780.
- 14 Raman SR, Man KKC, Bahmanyar S, *et al.* Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. *Lancet Psychiatry*. 2018;5:824–35.

16. ANNEXES

ANNEX I. Code lists for medications and conditions

Study medication

Medication	Class	ATC code	RxNorm	Concept Id in OMOP	Include descendants
methylphenidate	stimulants	N06BA04	6901	705944	Yes
dexamphetamine	stimulants	N06BA02	3288	719311	Yes
lisdexamfetamine	stimulants	N06BA12	700810	709567	Yes
atomoxetine	non-stimulants	N06BA09	38400	742185	Yes
guanfacine	non-stimulants	C02AC02	40114	1344965	Yes

Indications

Concept Id	Code	Name	Domain	Vocabulary
ADHD				
40480225	444613000	Adult attention deficit hyperactivity disorder	Condition	SNOMED
438409	406506008	Attention deficit hyperactivity disorder	Condition	SNOMED
4149904	31177006	Attention deficit hyperactivity disorder, combined type	Condition	SNOMED
45765796	702815001	Attention deficit hyperactivity disorder, inattentive presentation (restrictive)	Condition	SNOMED
4253962	7461003	Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type	Condition	SNOMED
44784525	698692009	Attention deficit hyperactivity disorder, predominantly hyperactive impulsive type in remission	Condition	SNOMED
4149353	35253001	Attention deficit hyperactivity disorder, predominantly inattentive type	Condition	SNOMED
44782517	698689005	Attention deficit hyperactivity disorder, predominantly inattentive type in remission	Condition	SNOMED
440086	192127007	Child attention deficit disorder	Condition	SNOMED
4041692	229715008	Deficits in attention motor control and perception	Condition	SNOMED
4047120	229712006	Disorders of attention and motor control	Condition	SNOMED
1340259	OMOP5165914	Exacerbation of attention deficit hyperactivity disorder	Condition	OMOP Extension
437261	192131001	Hyperkinesis with developmental delay	Condition	SNOMED
438132	192132008	Hyperkinetic conduct disorder	Condition	SNOMED
4262921	46745001	Hyperkinetic syndrome with developmental delay	Condition	SNOMED
4085043	247762003	Reduced concentration span	Condition	SNOMED
4049391	23148009	Undifferentiated attention deficit disorder	Condition	SNOMED
45765568	702536007	Stimulant drug therapy for attention deficit hyperactivity disorder	Procedure	SNOMED

45765570	702538008	Drug therapy for attention deficit hyperactivity disorder	Procedure	SNOMED
Narcolepsy				
437854	193042000	Cataplexy and narcolepsy	Condition	SNOMED
436100	60380001	Narcolepsy	Condition	SNOMED
1340405	OMOP5166060	Exacerbation of narcolepsy	Condition	OMOP Extension
42536721	735676003	Narcolepsy type 1	Condition	SNOMED
36716323	722293005	Autosomal dominant cerebellar ataxia, deafness, and narcolepsy syndrome	Condition	SNOMED
43531721	91521000119104	Narcolepsy without cataplexy	Condition	SNOMED
762958	434241000124107	Secondary narcolepsy	Condition	SNOMED
Hypertension (with all descendants)				
316866	38341003	Hypertension disorder	Condition	SNOMED

Other off-label indications

Condition	concept_id	concept_name	domain_id	vocabulary_id
autism	439703	Active infantile autism	Condition	SNOMED
autism	439702	Residual infantile autism	Condition	SNOMED
autism	4338037	Atypical autism	Condition	SNOMED
autism	439776	Autism spectrum disorder	Condition	SNOMED
autism	4254211	Infantile autism	Condition	SNOMED
autism	40482738	Active but odd autism	Condition	SNOMED
autism	45765723	High-functioning autism	Condition	SNOMED
autism	36716319	Autism and facial port-wine stain syndrome	Condition	SNOMED
autism	37116742	Autism spectrum disorder, epilepsy, arthrogryposis syndrome	Condition	SNOMED
autism	35624210	ADNP-related multiple congenital anomalies, intellectual disability, autism spectrum disorder	Condition	SNOMED
autism	36674903	Developmental delay with autism spectrum disorder and gait instability	Condition	SNOMED
autism	36675122	Autism epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency	Condition	SNOMED
autism	36675177	Autism spectrum disorder due to AUTS2 deficiency	Condition	SNOMED
autism	37204430	Macrocephaly, intellectual disability, autism syndrome	Condition	SNOMED
autism	3655811	Pervasive developmental disorder with disorder of intellectual development without loss of previously acquired skills	Condition	SNOMED
autism	3661684	Pervasive developmental disorder with disorder of intellectual development	Condition	SNOMED

		and absence of functional language with loss of previously acquired skills		
autism	3661689	Pervasive developmental disorder with complete impairment of functional language with loss of previously acquired skills	Condition	SNOMED
autism	439780	Autistic disorder	Condition	SNOMED
autism	3661686	Pervasive developmental disorder with disorder of intellectual development and complete impairment of functional language with loss of previously acquired skills	Condition	SNOMED
autism	3661691	Pervasive developmental disorder with cognitive developmental delay and marked impairment of functional language	Condition	SNOMED
autism	3661694	Pervasive developmental disorder with cognitive developmental delay and complete impairment of functional language	Condition	SNOMED
autism	4034867	Adenylosuccinate lyase deficiency	Condition	SNOMED
autism	434902	Autistic disorder of childhood onset	Condition	SNOMED
autism	3655812	Pervasive developmental disorder with disorder of intellectual development with loss of previously acquired skills	Condition	SNOMED
autism	3661680	Pervasive developmental disorder with disorder of intellectual development and pervasive impairment of functional language without loss of previously acquired skills	Condition	SNOMED
autism	3661682	Pervasive developmental disorder with disorder of intellectual development and marked impairment of functional language without loss of previously acquired skills	Condition	SNOMED
autism	3661687	Pervasive developmental disorder with severe impairment of functional language with loss of previously acquired skills	Condition	SNOMED
autism	3661681	Pervasive developmental disorder with disorder of intellectual development and marked impairment of functional language with loss of previously acquired skills	Condition	SNOMED
autism	3661688	Pervasive developmental disorder with severe impairment of functional language without loss of previously acquired skills	Condition	SNOMED
autism	3661678	Pervasive developmental disorder with marked impairment of functional language without loss of previously acquired skills	Condition	SNOMED

autism	3661683	Pervasive developmental disorder with disorder of intellectual development and complete impairment of functional language without loss of previously acquired skills	Condition	SNOMED
autism	3661693	Pervasive developmental disorder with absence of functional language	Condition	SNOMED
autism	4203306	Akinetic mutism	Condition	SNOMED
autism	3661679	Pervasive developmental disorder with impairment of functional language	Condition	SNOMED
autism	3661677	Pervasive developmental disorder with marked impairment of functional language with loss of previously acquired skills	Condition	SNOMED
autism	3661690	Pervasive developmental disorder with complete impairment of functional language without loss of previously acquired skills	Condition	SNOMED
autism	3661692	Pervasive developmental disorder with complete impairment of functional language	Condition	SNOMED
autism	439705	Active disintegrative psychoses	Condition	SNOMED
autism	43020503	Pervasive developmental disorder of residual state	Condition	SNOMED
autism	45765499	FOXG1 syndrome	Condition	SNOMED
autism	37016769	Pathological demand avoidance	Condition	SNOMED
autism	4189466	Autistic spectrum disorder with isolated skills	Condition	SNOMED
autism	4332239	Savant syndrome	Condition	SNOMED
autism	36717734	1p21.3 microdeletion syndrome	Condition	SNOMED
autism	45769394	Residual Asperger's disorder	Condition	SNOMED
autism	37109594	Isodicentric chromosome 15 syndrome	Condition	SNOMED
autism	439704	Residual disintegrative psychoses	Condition	SNOMED
autism	4053178	Asperger's disorder	Condition	SNOMED
fatigue	1340332	Exacerbation of fatigue	Condition	OMOP Extension
fatigue	607123	Reduced level of fatigue	Condition	SNOMED
fatigue	442024	Transient heat fatigue	Condition	SNOMED
fatigue	4063119	Peripheral muscle fatigue	Condition	SNOMED
fatigue	4062571	Fatigue during pregnancy - delivered	Condition	SNOMED
fatigue	4060299	Fatigue during pregnancy - not delivered	Condition	SNOMED
fatigue	4062925	Fatigue during pregnancy with postnatal complication	Condition	SNOMED
fatigue	4347293	Severe systemic illness respiratory muscle fatigue	Condition	SNOMED

fatigue	4092860	Rapid fatigue of gait	Condition	SNOMED
fatigue	439926	Malaise and fatigue	Condition	SNOMED
fatigue	4209103	Accommodative fatigue	Condition	SNOMED
fatigue	44793521	Severe chronic fatigue syndrome	Condition	SNOMED
fatigue	44793522	Moderate chronic fatigue syndrome	Condition	SNOMED
fatigue	44793523	Mild chronic fatigue syndrome	Condition	SNOMED
fatigue	4221911	Fatigue associated with AIDS	Condition	SNOMED
fatigue	40481844	Psychogenic fatigue	Condition	SNOMED
fatigue	40484614	Postexertional fatigue	Condition	SNOMED
fatigue	4202045	Postviral fatigue syndrome	Condition	SNOMED
fatigue	432738	Chronic fatigue syndrome	Condition	SNOMED
fatigue	4247433	Combat fatigue	Condition	SNOMED
fatigue	4279937	Low frequency muscle fatigue	Condition	SNOMED
fatigue	45772721	Fatigue due to treatment	Condition	SNOMED
fatigue	37396808	Cancer-related fatigue	Condition	SNOMED
fatigue	37205051	Fatigue due to chemotherapy	Condition	SNOMED
fatigue	37205052	Fatigue due to radiation therapy	Condition	SNOMED
fatigue	4193374	Central muscle fatigue	Condition	SNOMED
fatigue	4193763	High frequency muscle fatigue	Condition	SNOMED
fatigue	4214612	Muscle fatigue	Condition	SNOMED
fatigue	4223659	Fatigue	Condition	SNOMED
fatigue	4230221	Fatigue during pregnancy	Condition	SNOMED
fatigue	36686942	Bilateral weakness of upper limbs	Condition	SNOMED
fatigue	4060217	Heavy feeling	Condition	SNOMED
fatigue	4149857	Tired all the time	Condition	SNOMED
fatigue	4090207	Senile asthenia	Condition	SNOMED
fatigue	437113	Asthenia	Condition	SNOMED
fatigue	4074624	Tired	Condition	SNOMED
fatigue	765190	Asthenia due to disease	Condition	SNOMED
fatigue	4093848	Attacks of weakness	Condition	SNOMED
fatigue	4086973	Tired on least exertion	Condition	SNOMED
fatigue	37017316	Occasionally tired	Condition	SNOMED
fatigue	44782753	Weakness as a late effect of stroke	Condition	SNOMED
fatigue	4059010	Heavy legs	Condition	SNOMED
fatigue	4161600	Sensation of heaviness in limbs	Condition	SNOMED
eating_disorder	42689695	Eating disorder co-occurrent with diabetes mellitus type 1	Condition	SNOMED
eating_disorder	4253315	Nocturnal sleep-related eating disorder	Condition	SNOMED
eating_disorder	4144892	Eating disorder in remission	Condition	SNOMED

eating_disorder	439002	Eating disorder	Condition	SNOMED
eating_disorder	609050	Bulimia nervosa in full remission	Condition	SNOMED
eating_disorder	609049	Bulimia nervosa in partial remission	Condition	SNOMED
eating_disorder	44784528	Anorexia nervosa in remission	Condition	SNOMED
eating_disorder	44784532	Bulimia nervosa in remission	Condition	SNOMED
eating_disorder	4262968	Rumination disorder of infancy	Condition	SNOMED
eating_disorder	4085361	Self-induced purging to lose weight	Condition	SNOMED
eating_disorder	4103560	Non-organic infant feeding disturbance	Condition	SNOMED
eating_disorder	4152972	Overeating associated with other psychological disturbances	Condition	SNOMED
eating_disorder	4269485	Anorexia nervosa, binge-eating purging type	Condition	SNOMED
eating_disorder	37109945	Dangerously low body weight co-occurrent and due to anorexia nervosa of restricting type	Observation	SNOMED
eating_disorder	45767550	Self-induced vomiting to lose weight	Condition	SNOMED
eating_disorder	37109946	Dangerously low body weight co-occurrent and due to anorexia nervosa of binge-eating purging type	Observation	SNOMED
eating_disorder	4245170	Bulimia nervosa, non-purging type	Condition	SNOMED
eating_disorder	436675	Anorexia nervosa	Condition	SNOMED
eating_disorder	45763720	Avoidant restrictive food intake disorder	Condition	SNOMED
eating_disorder	3655965	Orthorexia nervosa	Condition	SNOMED
eating_disorder	36716719	Adult rumination syndrome of ingested food	Condition	SNOMED
eating_disorder	4333684	Atypical bulimia nervosa	Condition	SNOMED
eating_disorder	4143677	Developmental delay in feeding	Condition	SNOMED
eating_disorder	36717597	Anorexia nervosa co-occurrent with significantly low body weight	Observation	SNOMED
eating_disorder	4208913	Binge eating disorder	Observation	SNOMED
eating_disorder	4242221	Rumination disorder	Condition	SNOMED
eating_disorder	4139256	Bulimia nervosa, purging type	Condition	SNOMED
eating_disorder	437839	Pica	Condition	SNOMED
eating_disorder	37109947	Significantly low body weight co-occurrent and due to anorexia nervosa of restricting type	Observation	SNOMED
eating_disorder	4250314	Feeding disorder of infancy OR early childhood	Condition	SNOMED
eating_disorder	4173812	Psychogenic overeating	Condition	SNOMED
eating_disorder	4333682	Weight fixation	Condition	SNOMED
eating_disorder	4333683	Atypical anorexia nervosa	Condition	SNOMED
eating_disorder	36716779	Anorexia nervosa co-occurrent with dangerously low body weight	Observation	SNOMED

eating_disorder	4300305	Anorexia nervosa, restricting type	Condition	SNOMED
eating_disorder	4091520	Self-induced purging	Condition	SNOMED
eating_disorder	4102962	Non-organic loss of appetite	Condition	SNOMED
eating_disorder	4100683	Pica of infancy and childhood	Condition	SNOMED
eating_disorder	438407	Bulimia nervosa	Condition	SNOMED
eating_disorder	46285098	Acquired delay in feeding	Condition	SNOMED
eating_disorder	37118987	Significantly low body weight co-occurrent and due to anorexia nervosa of binge-eating purging type	Observation	SNOMED
eating_disorder	35609103	Emergency hospital admission to eating disorders service	Observation	SNOMED
eating_disorder	4208913	Binge eating disorder	Observation	SNOMED
eating_disorder	44808062	Eating disorders service	Observation	SNOMED
cognitive_dysfunction	3188590	Cognitive dysfunction with epilepsy	Condition	Nebraska Lexicon
cognitive_dysfunction	3174547	Cognitive dysfunction accompanying multiple sclerosis	Condition	Nebraska Lexicon
cognitive_dysfunction	36675110	Postoperative cognitive dysfunction	Condition	SNOMED
cognitive_dysfunction	44782725	Cognitive changes due to organic disorder	Condition	SNOMED
cognitive_dysfunction	4047110	Language-related cognitive disorder	Condition	SNOMED
cognitive_dysfunction	4297400	Mild cognitive disorder	Condition	SNOMED
cognitive_dysfunction	40480615	Cognitive disorder	Condition	SNOMED
cognitive_dysfunction	44784524	Cognitive disorder in remission	Condition	SNOMED
cognitive_dysfunction	46271045	Neurocognitive disorder	Condition	SNOMED
cognitive_dysfunction	37396726	Cognitive communication disorder	Condition	SNOMED
cognitive_dysfunction	37110498	Cognitive impairment co-occurrent and due to primary psychotic disorder	Condition	SNOMED
cognitive_dysfunction	42537139	Dissociative neurological symptom disorder co-occurrent with cognitive symptoms	Condition	SNOMED
cognitive_dysfunction	3654469	Amnesic mild cognitive disorder	Condition	SNOMED
cognitive_dysfunction	3661691	Pervasive developmental disorder with cognitive developmental delay and marked impairment of functional language	Condition	SNOMED
cognitive_dysfunction	3661694	Pervasive developmental disorder with cognitive developmental delay and complete impairment of functional language	Condition	SNOMED
cognitive_dysfunction	443432	Impaired cognition	Condition	SNOMED
cognitive_dysfunction	42535706	Cognitive deficit due to and following embolic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	36687122	Human immunodeficiency virus infection with cognitive impairment	Condition	SNOMED

cognitive_dysfunction	42539270	Cognitive deficit due to and following nontraumatic subarachnoid haemorrhage	Condition	SNOMED
cognitive_dysfunction	3654907	Cognitive impairment caused by ingestible alcohol	Condition	SNOMED
cognitive_dysfunction	4137543	Cognitive developmental delay	Condition	SNOMED
cognitive_dysfunction	42539271	Cognitive deficit due to and following nontraumatic intracerebral haemorrhage	Condition	SNOMED
cognitive_dysfunction	43020439	Borderline cognitive developmental delay	Condition	SNOMED
cognitive_dysfunction	4003688	Indication for modification of patient cognitive status	Condition	SNOMED
cognitive_dysfunction	35607999	Cognitive impairment, coarse facies, heart defects, obesity, pulmonary involvement, short stature, skeletal dysplasia syndrome	Condition	SNOMED
cognitive_dysfunction	42539256	Cognitive deficit due to and following cerebrovascular disease	Condition	SNOMED
cognitive_dysfunction	36676518	Infantile-onset mesial temporal lobe epilepsy with severe cognitive regression	Condition	SNOMED
cognitive_dysfunction	40482301	Residual cognitive deficit as late effect of cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	42535681	Cognitive deficit due to and following ischemic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	35622315	Hypotonia, speech impairment, severe cognitive delay syndrome	Condition	SNOMED
cognitive_dysfunction	42535682	Cognitive deficit due to and following haemorrhagic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	3655811	Pervasive developmental disorder with disorder of intellectual development without loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661684	Pervasive developmental disorder with disorder of intellectual development and absence of functional language with loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661686	Pervasive developmental disorder with disorder of intellectual development and complete impairment of functional language with loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661680	Pervasive developmental disorder with disorder of intellectual development and pervasive impairment of functional language without loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661682	Pervasive developmental disorder with disorder of intellectual development and marked impairment of functional	Condition	SNOMED

		language without loss of previously acquired skills		
cognitive_dysfunction	3655812	Pervasive developmental disorder with disorder of intellectual development with loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661681	Pervasive developmental disorder with disorder of intellectual development and marked impairment of functional language with loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	3661683	Pervasive developmental disorder with disorder of intellectual development and complete impairment of functional language without loss of previously acquired skills	Condition	SNOMED
cognitive_dysfunction	4162498	Organic amnesia of language	Condition	SNOMED
cognitive_dysfunction	4229448	Anterograde amnesia	Condition	SNOMED
cognitive_dysfunction	4145069	Transient memory loss	Condition	SNOMED
cognitive_dysfunction	439795	Minimal cognitive impairment	Condition	SNOMED
cognitive_dysfunction	37309660	Memory deficit due to and following haemorrhagic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	42538566	Cognitive impairment due to toxicity of substance	Condition	SNOMED
cognitive_dysfunction	4036509	Impaired environmental interpretation syndrome	Condition	SNOMED
cognitive_dysfunction	439147	Amnesia	Condition	SNOMED
cognitive_dysfunction	437306	Transient global amnesia	Condition	SNOMED
cognitive_dysfunction	44784521	Post-traumatic dementia with behavioural change	Condition	SNOMED
cognitive_dysfunction	37309661	Memory deficit due to and following ischemic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	4076654	Memory lapses	Condition	SNOMED
cognitive_dysfunction	1340245	Exacerbation of amnesia	Condition	OMOP Extension
cognitive_dysfunction	37309663	Memory deficit due to and following cerebrovascular disease	Condition	SNOMED
cognitive_dysfunction	4264146	Amnesia for remote events	Condition	SNOMED
cognitive_dysfunction	4166262	Disturbance of memory for order of events	Condition	SNOMED
cognitive_dysfunction	4206332	Forgetful	Condition	SNOMED
cognitive_dysfunction	4304008	Memory impairment	Condition	SNOMED
cognitive_dysfunction	45765900	Severe cognitive impairment	Condition	SNOMED
cognitive_dysfunction	4022572	Disturbance of cognitive learning	Condition	SNOMED
cognitive_dysfunction	4076655	Mixes past with present	Condition	SNOMED
cognitive_dysfunction	4152488	Impairment of registration	Condition	SNOMED
cognitive_dysfunction	4099961	Mild memory disturbance	Condition	SNOMED

cognitive_dysfunction	609091	Memory deficit due to and following spontaneous subarachnoid haemorrhage	Condition	SNOMED
cognitive_dysfunction	609090	Memory deficit due to and following spontaneous intracerebral haemorrhage	Condition	SNOMED
cognitive_dysfunction	4005009	Lack of thinking ability	Condition	SNOMED
cognitive_dysfunction	4083456	Amnesia for important personal information	Condition	SNOMED
cognitive_dysfunction	37309662	Memory deficit due to and following cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	4009705	Age-related cognitive decline	Condition	SNOMED
cognitive_dysfunction	44782727	Depressed mood in Alzheimer's disease	Condition	SNOMED
cognitive_dysfunction	4012209	Temporary loss of memory	Condition	SNOMED
cognitive_dysfunction	45765899	Moderate cognitive impairment	Condition	SNOMED
cognitive_dysfunction	37016192	Cognitive deficit in attention	Condition	SNOMED
cognitive_dysfunction	4296610	Information conversion problem	Condition	SNOMED
cognitive_dysfunction	3179559	Cognitive deficit complicating stroke	Condition	Nebraska Lexicon
cognitive_dysfunction	609092	Memory deficit due to and following embolic cerebrovascular accident	Condition	SNOMED
cognitive_dysfunction	4074319	Minor memory lapses	Condition	SNOMED
cognitive_dysfunction	44784643	Altered behaviour in Alzheimer's disease	Condition	SNOMED
cognitive_dysfunction	4138824	Paramnesia	Condition	SNOMED
cognitive_dysfunction	4132117	Retrospective falsification	Condition	SNOMED
cognitive_dysfunction	42537141	Impaired executive functioning	Condition	SNOMED
cognitive_dysfunction	4193675	Transient epileptic amnesia	Condition	SNOMED
cognitive_dysfunction	4092086	Amnesia for day to day facts	Condition	SNOMED
cognitive_dysfunction	4173661	Post-traumatic amnesia	Condition	SNOMED
cognitive_dysfunction	4198081	Retrograde amnesia	Condition	SNOMED
cognitive_dysfunction	4171718	Amnesia for recent events	Condition	SNOMED
cognitive_dysfunction	44782432	Early onset Alzheimer's disease with behavioural disturbance	Condition	SNOMED
addiction	4338024	Absinthe addiction	Condition	SNOMED
addiction	4139144	Addiction	Condition	SNOMED
addiction	4215081	Physical addiction	Condition	SNOMED
addiction	4312088	Psychological addiction	Condition	SNOMED
addiction	4102814	Glue sniffing dependence	Condition	SNOMED
addiction	4333676	Heroin dependence	Condition	SNOMED
addiction	4275756	Dependent drug abuse	Condition	SNOMED
addiction	4102815	Glue sniffing dependence, continuous	Condition	SNOMED

addiction	4103410	Glue sniffing dependence in remission	Condition	SNOMED
addiction	4100517	Glue sniffing dependence, episodic	Condition	SNOMED
behavioural_disorder	441547	Oppositional defiant disorder	Condition	SNOMED
behavioural_disorder	37110475	Oppositional defiant disorder co-occurrent with chronic irritability-anger	Condition	SNOMED
behavioural_disorder	37110476	Oppositional defiant disorder co-occurrent with chronic irritability-anger with normal prosocial emotions	Condition	SNOMED
behavioural_disorder	37110477	Oppositional defiant disorder without chronic irritability-anger	Condition	SNOMED
behavioural_disorder	37110478	Oppositional defiant disorder without chronic irritability-anger with limited prosocial emotions	Condition	SNOMED
behavioural_disorder	37110479	Oppositional defiant disorder without chronic irritability-anger with normal prosocial emotions	Condition	SNOMED
behavioural_disorder	437843	Conduct disorder, childhood-onset type	Condition	SNOMED
behavioural_disorder	433451	Aggressive unsocial conduct disorder	Condition	SNOMED
behavioural_disorder	4105183	Childhood disorder of conduct and emotion	Condition	SNOMED
behavioural_disorder	438132	Hyperkinetic conduct disorder	Condition	SNOMED
behavioural_disorder	4338038	Conduct disorder - in family context	Condition	SNOMED
behavioural_disorder	4335176	Conduct disorder - unsocialized	Condition	SNOMED
behavioural_disorder	4333687	Depressive conduct disorder	Condition	SNOMED
behavioural_disorder	440697	Nonaggressive unsocial conduct disorder	Condition	SNOMED
behavioural_disorder	443617	Conduct disorder	Condition	SNOMED
behavioural_disorder	439800	Conduct disorder, adolescent-onset type	Condition	SNOMED
behavioural_disorder	4268025	Conduct disorder, undifferentiated type	Condition	SNOMED
behavioural_disorder	4279455	Conduct disorder, group type	Condition	SNOMED
behavioural_disorder	436076	Adjustment disorder with mixed disturbance of emotions AND conduct	Condition	SNOMED
behavioural_disorder	44784531	Adjustment disorder with mixed disturbance of emotions and conduct in remission	Condition	SNOMED
behavioural_disorder	44782933	Conduct disorder in remission	Condition	SNOMED
behavioural_disorder	37110480	Childhood onset conduct-dissocial disorder with limited prosocial emotions	Condition	SNOMED
behavioural_disorder	37110481	Childhood onset conduct-dissocial disorder with normal prosocial emotions	Condition	SNOMED
behavioural_disorder	37110482	Adolescent onset conduct-dissocial disorder	Condition	SNOMED

behavioural_disorder	37110483	Adolescent onset conduct-dissocial disorder with limited prosocial emotions	Condition	SNOMED
behavioural_disorder	37110484	Adolescent onset conduct-dissocial disorder with normal prosocial emotions	Condition	SNOMED
behavioural_disorder	4254395	Conduct disorder, solitary aggressive type	Condition	SNOMED
behavioural_disorder	42538606	Childhood onset conduct-dissocial disorder	Condition	SNOMED
behavioural_disorder	435799	Adjustment disorder with disturbance of conduct	Condition	SNOMED
behavioural_disorder	440989	Intermittent explosive disorder	Condition	SNOMED
behavioural_disorder	37396201	Disruptive mood dysregulation disorder	Condition	SNOMED
behavioural_disorder	432877	Socialized behaviour disorder	Condition	SNOMED
behavioural_disorder	4100089	Sibling jealousy	Condition	SNOMED
behavioural_disorder	4099964	Group delinquency	Condition	SNOMED
behavioural_disorder	4146721	Unsocial childhood truancy	Condition	SNOMED
behavioural_disorder	4099966	Neurotic delinquency	Condition	SNOMED
behavioural_disorder	4103571	Adjustment reaction with antisocial behaviour	Condition	SNOMED
behavioural_disorder	4103570	Adjustment reaction with aggression	Condition	SNOMED
behavioural_disorder	4102970	Adjustment reaction with destructiveness	Condition	SNOMED
major depressive disorder	432285	Recurrent major depressive episodes	Condition	SNOMED
major depressive disorder	432883	Recurrent major depressive episodes, moderate	Condition	SNOMED
major depressive disorder	433991	Recurrent major depression in remission	Condition	SNOMED
major depressive disorder	434911	Recurrent major depressive episodes, severe, with psychosis	Condition	SNOMED
major depressive disorder	435220	Severe recurrent major depression without psychotic features	Condition	SNOMED
major depressive disorder	438406	Severe major depression, single episode, with psychotic features	Condition	SNOMED
major depressive disorder	438998	Recurrent major depressive episodes, mild	Condition	SNOMED
major depressive disorder	439259	Single major depressive episode, severe, with psychosis	Condition	SNOMED
major depressive disorder	441534	Severe major depression, single episode, without psychotic features	Condition	SNOMED
major depressive disorder	4031328	Chronic major depressive disorder, single episode	Condition	SNOMED
major depressive disorder	4034842	Severe recurrent major depression with psychotic features, mood-incongruent	Condition	SNOMED

major depressive disorder	4049623	Moderate major depression, single episode	Condition	SNOMED
major depressive disorder	4067409	Severe major depression, single episode, with psychotic features, mood-incongruent	Condition	SNOMED
major depressive disorder	4077577	Moderate recurrent major depression	Condition	SNOMED
major depressive disorder	4093584	Major depressive disorder, single episode with postpartum onset	Condition	SNOMED
major depressive disorder	4094358	Chronic recurrent major depressive disorder	Condition	SNOMED
major depressive disorder	4141292	Severe recurrent major depression with psychotic features, mood-congruent	Condition	SNOMED
major depressive disorder	4141454	Recurrent major depression in partial remission	Condition	SNOMED
major depressive disorder	4144233	Severe major depression with psychotic features, mood-congruent	Condition	SNOMED
major depressive disorder	4148630	Major depression in partial remission	Condition	SNOMED
major depressive disorder	4154309	Severe recurrent major depression with psychotic features	Condition	SNOMED
major depressive disorder	4154391	Major depression, melancholic type	Condition	SNOMED
major depressive disorder	4176002	Major depression in remission	Condition	SNOMED
major depressive disorder	4181807	Major depressive disorder, single episode with atypical features	Condition	SNOMED
major depressive disorder	4195572	Mild major depression, single episode	Condition	SNOMED
major depressive disorder	4205471	Recurrent major depressive disorder with melancholic features	Condition	SNOMED
major depressive disorder	4220023	Recurrent major depressive disorder with catatonic features	Condition	SNOMED
major depressive disorder	4228802	Mild recurrent major depression	Condition	SNOMED
major depressive disorder	4243822	Severe major depression with psychotic features, mood-incongruent	Condition	SNOMED
major depressive disorder	4250023	Severe major depression with psychotic features	Condition	SNOMED
major depressive disorder	4270907	Major depressive disorder, single episode with melancholic features	Condition	SNOMED
major depressive disorder	4282096	Major depression, single episode	Condition	SNOMED
major depressive disorder	4282316	Recurrent major depression	Condition	SNOMED
major depressive disorder	4287238	Major depressive disorder, single episode with catatonic features	Condition	SNOMED
major depressive disorder	4299785	Severe major depression, single episode, with psychotic features, mood-congruent	Condition	SNOMED
major depressive disorder	4304140	Recurrent major depressive disorder with atypical features	Condition	SNOMED
major depressive disorder	4307111	Moderate major depression	Condition	SNOMED

major depressive disorder	4323418	Major depression single episode, in partial remission	Condition	SNOMED
major depressive disorder	4324959	Recurrent major depressive disorder with postpartum onset	Condition	SNOMED
major depressive disorder	4327337	Severe major depression without psychotic features	Condition	SNOMED
major depressive disorder	4336957	Mild major depression	Condition	SNOMED
major depressive disorder	35615151	Recurrent mild major depressive disorder co-occurent with anxiety	Condition	SNOMED
major depressive disorder	35615152	Recurrent severe major depressive disorder co-occurent with anxiety	Condition	SNOMED
major depressive disorder	35615153	Recurrent moderate major depressive disorder co-occurent with anxiety	Condition	SNOMED
major depressive disorder	35615155	Recurrent major depressive disorder in partial remission co-occurent with anxiety	Condition	SNOMED
major depressive disorder	36714389	Moderately severe major depression	Condition	SNOMED
major depressive disorder	36714997	Minimal recurrent major depression	Condition	SNOMED
major depressive disorder	36714998	Moderately severe recurrent major depression	Condition	SNOMED
major depressive disorder	36714999	Minimal major depression single episode	Condition	SNOMED
major depressive disorder	36715000	Minimal major depression	Condition	SNOMED
major depressive disorder	36717389	Moderately severe major depression single episode	Condition	SNOMED
major depressive disorder	37109052	Mild major depressive disorder co-occurent with anxiety single episode	Condition	SNOMED
major depressive disorder	37109053	Moderate major depressive disorder co-occurent with anxiety single episode	Condition	SNOMED
major depressive disorder	37109054	Severe major depressive disorder co-occurent with anxiety single episode	Condition	SNOMED
major depressive disorder	37111697	Major depression with psychotic features	Condition	SNOMED
major depressive disorder	42534817	Postpartum major depression in remission	Condition	SNOMED
major depressive disorder	42872411	Severe major depression, single episode	Condition	SNOMED
major depressive disorder	42872722	Severe major depression	Condition	SNOMED
major depressive disorder	43531624	Severe recurrent major depression	Condition	SNOMED
major depressive disorder	44805542	Recurrent major depressive episodes, severe	Condition	SNOMED
major depressive disorder	44805549	Recurrent major depressive episodes, in partial remission	Condition	SNOMED
major depressive disorder	44805550	Single major depressive episode, in remission	Condition	SNOMED

major depressive disorder	44805668	Single major depressive episode, severe, with psychosis, psychosis in remission	Condition	SNOMED
major depressive disorder	44805669	Recurrent major depressive episodes, severe, with psychosis, psychosis in remission	Condition	SNOMED
major depressive disorder	44813499	Recurrent major depressive episodes, in remission	Condition	SNOMED
mood_disorders	372599	Severe mixed bipolar I disorder without psychotic features	Condition	SNOMED
mood_disorders	373176	Organic mood disorder	Condition	SNOMED
mood_disorders	432290	Mild bipolar I disorder, single manic episode	Condition	SNOMED
mood_disorders	432866	Bipolar I disorder, single manic episode	Condition	SNOMED
mood_disorders	432876	Bipolar I disorder	Condition	SNOMED
mood_disorders	433440	Dysthymia	Condition	SNOMED
mood_disorders	433743	Mixed bipolar I disorder in remission	Condition	SNOMED
mood_disorders	433751	Prolonged depressive adjustment reaction	Condition	SNOMED
mood_disorders	433992	Bipolar affective disorder, currently manic, moderate	Condition	SNOMED
mood_disorders	435225	Depressed bipolar I disorder in full remission	Condition	SNOMED
mood_disorders	435226	Bipolar affective disorder, current episode mixed	Condition	SNOMED
mood_disorders	435520	Reactive depressive psychosis	Condition	SNOMED
mood_disorders	436072	Bipolar disorder in partial remission	Condition	SNOMED
mood_disorders	436075	Adjustment disorder with anxious mood	Condition	SNOMED
mood_disorders	436079	Mood disorder caused by drug	Condition	SNOMED
mood_disorders	436086	Manic bipolar I disorder in full remission	Condition	SNOMED
mood_disorders	436386	Severe depressed bipolar I disorder with psychotic features	Condition	SNOMED
mood_disorders	436665	Bipolar disorder	Condition	SNOMED
mood_disorders	437249	Recurrent manic episodes	Condition	SNOMED
mood_disorders	437250	Mild depressed bipolar I disorder	Condition	SNOMED
mood_disorders	437522	Severe mood disorder without psychotic features	Condition	SNOMED
mood_disorders	437528	Bipolar affective disorder, currently depressed, moderate	Condition	SNOMED
mood_disorders	437529	Mixed bipolar I disorder in partial remission	Condition	SNOMED
mood_disorders	437532	Recurrent manic episodes, severe, with psychosis	Condition	SNOMED

mood_disorders	437831	Recurrent manic episodes, in full remission	Condition	SNOMED
mood_disorders	438119	Recurrent manic episodes, mild	Condition	SNOMED
mood_disorders	438129	Severe manic bipolar I disorder with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	438405	Recurrent manic episodes, moderate	Condition	SNOMED
mood_disorders	438727	Atypical depressive disorder	Condition	SNOMED
mood_disorders	439001	Severe mixed bipolar I disorder with psychotic features	Condition	SNOMED
mood_disorders	439245	Mixed bipolar affective disorder, in full remission	Condition	SNOMED
mood_disorders	439246	Mixed bipolar affective disorder, severe, with psychosis	Condition	SNOMED
mood_disorders	439248	Mixed bipolar affective disorder, moderate	Condition	SNOMED
mood_disorders	439249	Mixed bipolar affective disorder, mild	Condition	SNOMED
mood_disorders	439250	Mixed bipolar affective disorder	Condition	SNOMED
mood_disorders	439251	Bipolar affective disorder, currently depressed, in full remission	Condition	SNOMED
mood_disorders	439253	Bipolar affective disorder, currently depressed, mild	Condition	SNOMED
mood_disorders	439254	Bipolar affective disorder, current episode depression	Condition	SNOMED
mood_disorders	439255	Bipolar affective disorder, currently manic, in full remission	Condition	SNOMED
mood_disorders	439256	Bipolar affective disorder, currently manic, severe, with psychosis	Condition	SNOMED
mood_disorders	439261	Single manic episode in full remission	Condition	SNOMED
mood_disorders	439262	Single manic episode, severe, with psychosis	Condition	SNOMED
mood_disorders	439272	Single manic episode, moderate	Condition	SNOMED
mood_disorders	439273	Single manic episode, mild	Condition	SNOMED
mood_disorders	439785	Moderate mixed bipolar I disorder	Condition	SNOMED
mood_disorders	440067	Moderate bipolar I disorder, single manic episode	Condition	SNOMED
mood_disorders	440078	Bipolar affective disorder, current episode manic	Condition	SNOMED
mood_disorders	440079	Mild mixed bipolar I disorder	Condition	SNOMED
mood_disorders	440383	Depressive disorder	Condition	SNOMED
mood_disorders	440696	Cyclothymia	Condition	SNOMED
mood_disorders	440698	Brief depressive adjustment reaction	Condition	SNOMED
mood_disorders	440980	Atypical manic disorder	Condition	SNOMED
mood_disorders	441834	Bipolar affective disorder, currently manic, mild	Condition	SNOMED

mood_disorders	441836	Depressed bipolar I disorder	Condition	SNOMED
mood_disorders	442306	Adjustment disorder with depressed mood	Condition	SNOMED
mood_disorders	442570	Severe depressed bipolar I disorder without psychotic features	Condition	SNOMED
mood_disorders	442600	Manic bipolar I disorder in partial remission	Condition	SNOMED
mood_disorders	443237	Manic disorder, single episode	Condition	SNOMED
mood_disorders	443797	Severe manic bipolar I disorder without psychotic features	Condition	SNOMED
mood_disorders	443864	Multi-infarct dementia with depression	Condition	SNOMED
mood_disorders	443906	Mixed bipolar I disorder	Condition	SNOMED
mood_disorders	444038	Psychoactive substance-induced organic mood disorder	Condition	SNOMED
mood_disorders	444100	Mood disorder	Condition	SNOMED
mood_disorders	607540	Treatment resistant depression	Condition	SNOMED
mood_disorders	607543	Persistent depressive disorder	Condition	SNOMED
mood_disorders	761111	Recurrent manic episodes in partial remission	Condition	SNOMED
mood_disorders	761947	Recurrent severe manic episodes	Condition	SNOMED
mood_disorders	762060	Chronic mood disorder	Condition	SNOMED
mood_disorders	1340265	Exacerbation of bipolar disorder	Condition	OMOP Extension
mood_disorders	1340305	Exacerbation of depressive disorder	Condition	OMOP Extension
mood_disorders	1340392	Exacerbation of major depressive disorder	Condition	OMOP Extension
mood_disorders	1340393	Exacerbation of mania	Condition	OMOP Extension
mood_disorders	3172581	Bipolar disease in pregnancy	Condition	Nebraska Lexicon
mood_disorders	3190612	Substance induced mood disorder	Condition	Nebraska Lexicon
mood_disorders	3654786	Mood disorder with manic symptoms caused by amphetamine and amphetamine derivative	Condition	SNOMED
mood_disorders	3654787	Mood disorder with mixed depressive and manic symptoms caused by amphetamine and amphetamine derivative	Condition	SNOMED
mood_disorders	3654788	Mood disorder with depressive symptoms caused by amphetamine and amphetamine derivative	Condition	SNOMED
mood_disorders	4000165	Severe bipolar II disorder, most recent episode major depressive with psychotic features, mood-congruent	Condition	SNOMED

mood_disorders	4001733	Chronic bipolar II disorder, most recent episode major depressive	Condition	SNOMED
mood_disorders	4009648	Mixed bipolar I disorder in full remission	Condition	SNOMED
mood_disorders	4012869	Cocaine-induced mood disorder	Condition	SNOMED
mood_disorders	4025677	Single episode of major depression in full remission	Condition	SNOMED
mood_disorders	4028027	Mild bipolar disorder	Condition	SNOMED
mood_disorders	4029464	Hallucinogen mood disorder	Condition	SNOMED
mood_disorders	4030102	Severe bipolar I disorder, single manic episode with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	4030856	Severe bipolar I disorder, single manic episode without psychotic features	Condition	SNOMED
mood_disorders	4031928	Severe mixed bipolar I disorder with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4033390	Bipolar I disorder, single manic episode with postpartum onset	Condition	SNOMED
mood_disorders	4037669	Bipolar II disorder, most recent episode major depressive	Condition	SNOMED
mood_disorders	4045263	Severe bipolar II disorder, most recent episode major depressive, in full remission	Condition	SNOMED
mood_disorders	4051448	Severe bipolar II disorder, most recent episode major depressive with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4057218	Late onset dysthymia	Condition	SNOMED
mood_disorders	4071442	Bipolar I disorder, most recent episode depressed with catatonic features	Condition	SNOMED
mood_disorders	4073401	Bipolar I disorder, most recent episode manic with catatonic features	Condition	SNOMED
mood_disorders	4092239	Seasonal affective disorder	Condition	SNOMED
mood_disorders	4094507	Severe depressed bipolar I disorder with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4096229	Early onset dysthymia	Condition	SNOMED
mood_disorders	4098302	Recurrent depression	Condition	SNOMED
mood_disorders	4102603	Severe manic bipolar I disorder with psychotic features	Condition	SNOMED
mood_disorders	4102936	Mood disorder with manic features due to general medical condition	Condition	SNOMED
mood_disorders	4102973	Postviral depression	Condition	SNOMED
mood_disorders	4103126	Drug-induced depressive state	Condition	SNOMED
mood_disorders	4103574	Chronic depression	Condition	SNOMED
mood_disorders	4103853	Sedative, hypnotic, AND/OR anxiolytic-induced mood disorder	Condition	SNOMED

mood_disorders	4105930	Opioid-induced mood disorder	Condition	SNOMED
mood_disorders	4107538	Bipolar I disorder, most recent episode depressed with atypical features	Condition	SNOMED
mood_disorders	4114950	Endogenous depression	Condition	SNOMED
mood_disorders	4129184	Severe postnatal depression	Condition	SNOMED
mood_disorders	4129842	Mild postnatal depression	Condition	SNOMED
mood_disorders	4131027	Severe bipolar disorder with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4132144	Severe mood disorder with psychotic features	Condition	SNOMED
mood_disorders	4133073	Maternity blues	Condition	SNOMED
mood_disorders	4141603	Severe manic bipolar I disorder with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4144519	Bipolar II disorder, most recent episode major depressive with melancholic features	Condition	SNOMED
mood_disorders	4145216	Premenstrual dysphoric disorder in remission	Condition	SNOMED
mood_disorders	4147991	Severe bipolar II disorder, most recent episode major depressive with psychotic features	Condition	SNOMED
mood_disorders	4148842	Bipolar I disorder, single manic episode, in full remission	Condition	SNOMED
mood_disorders	4148934	Bipolar II disorder, most recent episode major depressive with postpartum onset	Condition	SNOMED
mood_disorders	4149320	Mild depression	Condition	SNOMED
mood_disorders	4149321	Severe depression	Condition	SNOMED
mood_disorders	4150047	Secondary dysthymia early onset	Condition	SNOMED
mood_disorders	4150985	Bipolar I disorder, most recent episode hypomanic	Condition	SNOMED
mood_disorders	4151170	Moderate depression	Condition	SNOMED
mood_disorders	4152280	Major depressive disorder	Condition	SNOMED
mood_disorders	4154283	Severe bipolar I disorder	Condition	SNOMED
mood_disorders	4154805	Involutional depression	Condition	SNOMED
mood_disorders	4155208	Transitory postpartum mood disturbance	Condition	SNOMED
mood_disorders	4155798	Severe bipolar disorder	Condition	SNOMED
mood_disorders	4161200	Severe bipolar II disorder	Condition	SNOMED
mood_disorders	4166701	Manic bipolar I disorder in remission	Condition	SNOMED
mood_disorders	4168298	PCP mood disorder	Condition	SNOMED
mood_disorders	4168858	Endogenous depression - recurrent	Condition	SNOMED
mood_disorders	4172156	Bipolar II disorder, most recent episode hypomanic	Condition	SNOMED

mood_disorders	4174987	Minor depressive disorder	Condition	SNOMED
mood_disorders	4175329	Organic mood disorder of depressed type	Condition	SNOMED
mood_disorders	4177651	Depressed bipolar I disorder in partial remission	Condition	SNOMED
mood_disorders	4182998	Severe depressed bipolar I disorder with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	4184321	Amphetamine-induced mood disorder	Condition	SNOMED
mood_disorders	4185096	Bipolar II disorder, most recent episode major depressive with atypical features	Condition	SNOMED
mood_disorders	4192865	Bipolar I disorder, most recent episode depressed with melancholic features	Condition	SNOMED
mood_disorders	4194222	Moderate bipolar disorder	Condition	SNOMED
mood_disorders	4195158	Severe bipolar disorder with psychotic features	Condition	SNOMED
mood_disorders	4195680	Primary dysthymia late onset	Condition	SNOMED
mood_disorders	4197222	Stuporous depression	Condition	SNOMED
mood_disorders	4197669	Chronic bipolar I disorder, most recent episode depressed	Condition	SNOMED
mood_disorders	4200385	Severe bipolar disorder without psychotic features	Condition	SNOMED
mood_disorders	4201739	Depressed bipolar I disorder in remission	Condition	SNOMED
mood_disorders	4205002	Alcohol-induced mood disorder	Condition	SNOMED
mood_disorders	4210024	Bipolar I disorder, most recent episode manic with postpartum onset	Condition	SNOMED
mood_disorders	4215917	Mild manic bipolar I disorder	Condition	SNOMED
mood_disorders	4217940	Severe bipolar II disorder, most recent episode major depressive without psychotic features	Condition	SNOMED
mood_disorders	4218985	Amok	Condition	SNOMED
mood_disorders	4220617	Severe bipolar I disorder, single manic episode with psychotic features	Condition	SNOMED
mood_disorders	4220618	Bipolar disorder in full remission	Condition	SNOMED
mood_disorders	4223090	Menopausal depression	Condition	SNOMED
mood_disorders	4224639	Secondary dysthymia	Condition	SNOMED
mood_disorders	4224940	Schizoaffective disorder, depressive type	Condition	SNOMED
mood_disorders	4226155	Recurrent brief depressive disorder	Condition	SNOMED
mood_disorders	4232492	Inhalant-induced mood disorder	Condition	SNOMED
mood_disorders	4237734	Organic mood disorder of manic type	Condition	SNOMED
mood_disorders	4239453	Severe mood disorder with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	4239471	Postpartum depression	Condition	SNOMED

mood_disorders	4241158	Moderate mood disorder	Condition	SNOMED
mood_disorders	4242733	Premenstrual dysphoric disorder	Condition	SNOMED
mood_disorders	4243308	Primary dysthymia early onset	Condition	SNOMED
mood_disorders	4244078	Schizoaffective disorder, bipolar type	Condition	SNOMED
mood_disorders	4244690	Mood disorder in full remission	Condition	SNOMED
mood_disorders	4251178	Bipolar I disorder, most recent episode mixed with catatonic features	Condition	SNOMED
mood_disorders	4253782	Mood disorder in partial remission	Condition	SNOMED
mood_disorders	4262111	Moderate bipolar II disorder, most recent episode major depressive	Condition	SNOMED
mood_disorders	4262272	Severe bipolar II disorder, most recent episode major depressive, in remission	Condition	SNOMED
mood_disorders	4263748	Recurrent major depression in full remission	Condition	SNOMED
mood_disorders	4263770	Secondary dysthymia late onset	Condition	SNOMED
mood_disorders	4269143	Mild mood disorder	Condition	SNOMED
mood_disorders	4269493	Major depression in full remission	Condition	SNOMED
mood_disorders	4274957	Bipolar I disorder, most recent episode mixed with postpartum onset	Condition	SNOMED
mood_disorders	4276670	Severe mixed bipolar I disorder with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	4280361	Moderate depressed bipolar I disorder	Condition	SNOMED
mood_disorders	4283219	Severe bipolar II disorder, most recent episode major depressive, in partial remission	Condition	SNOMED
mood_disorders	4287544	Manic bipolar I disorder	Condition	SNOMED
mood_disorders	4289751	Severe mood disorder with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4295956	Mood disorder due to a general medical condition	Condition	SNOMED
mood_disorders	4298317	Mood disorder with major depressive-like episode due to general medical condition	Condition	SNOMED
mood_disorders	4301106	Bipolar I disorder, single manic episode, in partial remission	Condition	SNOMED
mood_disorders	4305966	Postoperative depression	Condition	SNOMED
mood_disorders	4307518	Organic mood disorder of mixed type	Condition	SNOMED
mood_disorders	4307804	Moderate manic bipolar I disorder	Condition	SNOMED
mood_disorders	4307951	Primary dysthymia	Condition	SNOMED
mood_disorders	4307956	Bipolar II disorder	Condition	SNOMED
mood_disorders	4308866	Agitated depression	Condition	SNOMED
mood_disorders	4310821	Bipolar disorder in remission	Condition	SNOMED

mood_disorders	4312736	Severe bipolar I disorder, single manic episode with psychotic features, mood-incongruent	Condition	SNOMED
mood_disorders	4314692	Reactive depression (situational)	Condition	SNOMED
mood_disorders	4322477	Severe bipolar disorder with psychotic features, mood-congruent	Condition	SNOMED
mood_disorders	4324945	Mild bipolar II disorder, most recent episode major depressive	Condition	SNOMED
mood_disorders	4327669	Bipolar I disorder, single manic episode, in remission	Condition	SNOMED
mood_disorders	4328217	Mood disorder with depressive features due to general medical condition	Condition	SNOMED
mood_disorders	4329560	Mood disorder with mixed features due to general medical condition	Condition	SNOMED
mood_disorders	4330846	Bipolar II disorder, most recent episode major depressive with catatonic features	Condition	SNOMED
mood_disorders	4332994	Post-schizophrenic depression	Condition	SNOMED
mood_disorders	4333670	Organic bipolar disorder	Condition	SNOMED
mood_disorders	4333677	Mania	Condition	SNOMED
mood_disorders	4333678	Hypomania	Condition	SNOMED
mood_disorders	4333679	Endogenous depression first episode	Condition	SNOMED
mood_disorders	4335160	Right hemispheric organic affective disorder	Condition	SNOMED
mood_disorders	4335170	Manic stupor	Condition	SNOMED
mood_disorders	4336405	Bipolar I disorder, most recent episode depressed with postpartum onset	Condition	SNOMED
mood_disorders	4336980	Generalized neuromuscular exhaustion syndrome	Condition	SNOMED
mood_disorders	4338019	Organic emotionally labile disorder	Condition	SNOMED
mood_disorders	4338029	Masked depression	Condition	SNOMED
mood_disorders	4338031	Mixed anxiety and depressive disorder	Condition	SNOMED
mood_disorders	4338812	Bipolar I disorder, single manic episode with catatonic features	Condition	SNOMED
mood_disorders	35609824	Recurrent reactive depressive episodes, severe, with psychosis	Condition	SNOMED
mood_disorders	35609842	Reactive depression, prolonged single episode	Condition	SNOMED
mood_disorders	35609843	Reactive depression, single episode	Condition	SNOMED
mood_disorders	35609844	Reactive depression, recurrent	Condition	SNOMED
mood_disorders	35609845	Reactive depression, first episode	Condition	SNOMED
mood_disorders	35610097	Recurrent depression with current severe episode and psychotic features	Condition	SNOMED

mood_disorders	35610108	Recurrent depression with current severe episode without psychotic features	Condition	SNOMED
mood_disorders	35610109	Recurrent depression with current moderate episode	Condition	SNOMED
mood_disorders	35610110	Mania with mood-congruent psychotic features	Condition	SNOMED
mood_disorders	35610111	Mania with mood-incongruent psychotic features	Condition	SNOMED
mood_disorders	35610112	Mania with psychotic features	Condition	SNOMED
mood_disorders	35615154	Recurrent major depressive disorder co-occurrent with anxiety in full remission	Condition	SNOMED
mood_disorders	35622934	Psychosis and severe depression co-occurrent and due to bipolar affective disorder	Condition	SNOMED
mood_disorders	35624743	Bipolar disorder, most recent episode depression	Condition	SNOMED
mood_disorders	35624744	Bipolar disorder, most recent episode manic	Condition	SNOMED
mood_disorders	35624745	Bipolar affective disorder, most recent episode mixed	Condition	SNOMED
mood_disorders	35624747	Bipolar I disorder, most recent episode manic	Condition	SNOMED
mood_disorders	35624748	Bipolar I disorder, most recent episode depression	Condition	SNOMED
mood_disorders	36684319	Adjustment disorder with mixed anxiety and depressed mood	Condition	SNOMED
mood_disorders	36712668	Perinatal depression	Condition	SNOMED
mood_disorders	36713698	Minimal depression	Condition	SNOMED
mood_disorders	36717092	Moderately severe depression	Condition	SNOMED
mood_disorders	37016268	Opioid-induced mood disorder due to opioid abuse	Condition	SNOMED
mood_disorders	37016718	Acute depression	Condition	SNOMED
mood_disorders	37018656	Depressive disorder in mother complicating pregnancy	Condition	SNOMED
mood_disorders	37018689	Opioid-induced mood disorder due to opioid dependence	Condition	SNOMED
mood_disorders	37109940	Bipolar type I disorder currently in full remission	Condition	SNOMED
mood_disorders	37109941	Secondary mood disorder	Condition	SNOMED
mood_disorders	37109950	Mood disorder with depressive symptoms caused by alcohol	Condition	SNOMED
mood_disorders	37109951	Mood disorder with manic symptoms caused by alcohol	Condition	SNOMED

mood_disorders	37109952	Mood disorder with mixed manic and depressive symptoms caused by alcohol	Condition	SNOMED
mood_disorders	37110428	Mood disorder with depressive symptoms caused by hypnotic	Condition	SNOMED
mood_disorders	37110429	Mood disorder with depressive symptoms caused by anxiolytic	Condition	SNOMED
mood_disorders	37110430	Mood disorder with manic symptoms caused by sedative	Condition	SNOMED
mood_disorders	37110431	Mood disorder with manic symptoms caused by hypnotic	Condition	SNOMED
mood_disorders	37110432	Mood disorder with mixed depressive and manic symptoms caused by sedative	Condition	SNOMED
mood_disorders	37110433	Mood disorder with mixed depressive and manic symptoms caused by hypnotic	Condition	SNOMED
mood_disorders	37110438	Mood disorder with depressive symptoms caused by cocaine	Condition	SNOMED
mood_disorders	37110439	Mood disorder with manic symptoms caused by cocaine	Condition	SNOMED
mood_disorders	37110452	Mood disorder caused by methylenedioxymethamphetamine	Condition	SNOMED
mood_disorders	37110463	Mood disorder caused by dissociative drug	Condition	SNOMED
mood_disorders	37110464	Mood disorder caused by ketamine	Condition	SNOMED
mood_disorders	37110495	Depressive symptoms due to primary psychotic disorder	Condition	SNOMED
mood_disorders	37117177	Bipolar type II disorder currently in full remission	Condition	SNOMED
mood_disorders	37117211	Mood disorder with depressive symptoms caused by sedative	Condition	SNOMED
mood_disorders	37117212	Mood disorder with manic symptoms caused by anxiolytic	Condition	SNOMED
mood_disorders	37117214	Mood disorder with mixed depressive and manic symptoms caused by cocaine	Condition	SNOMED
mood_disorders	37119148	Mood disorder with mixed depressive and manic symptoms caused by anxiolytic	Condition	SNOMED
mood_disorders	37209503	Depressive disorder caused by amphetamine	Condition	SNOMED
mood_disorders	37209504	Bipolar disorder caused by drug	Condition	SNOMED
mood_disorders	37309680	Depressive disorder caused by methamphetamine	Condition	SNOMED
mood_disorders	37309775	Mood disorder caused by methamphetamine	Condition	SNOMED
mood_disorders	37311915	Mood disorder caused by cannabis	Condition	SNOMED

mood_disorders	37312479	Antenatal depression	Condition	SNOMED
mood_disorders	37312550	Synthetic cannabinoid induced mood disorder	Condition	SNOMED
mood_disorders	37312578	Rapid cycling bipolar II disorder	Condition	SNOMED
mood_disorders	40481798	Chronic depressive personality disorder	Condition	SNOMED
mood_disorders	42538584	Mood disorder with depressive symptoms caused by opioid	Condition	SNOMED
mood_disorders	42538585	Mood disorder with mixed depressive and manic symptoms caused by opioid	Condition	SNOMED
mood_disorders	42538589	Mood disorder caused by stimulant	Condition	SNOMED
mood_disorders	42538590	Mood disorder with depressive symptoms caused by stimulant	Condition	SNOMED
mood_disorders	42538591	Mood disorder with mixed depressive and manic symptoms caused by stimulant	Condition	SNOMED
mood_disorders	42538595	Mood disorder with manic symptoms caused by hallucinogen	Condition	SNOMED
mood_disorders	42538596	Mood disorder with depressive symptoms caused by hallucinogen	Condition	SNOMED
mood_disorders	42538597	Mood disorder with mixed depressive and manic symptoms caused by hallucinogen	Condition	SNOMED
mood_disorders	42538598	Mood disorder with manic symptoms caused by volatile inhalant	Condition	SNOMED
mood_disorders	42538599	Mood disorder with depressive symptoms caused by volatile inhalant	Condition	SNOMED
mood_disorders	42538600	Mood disorder with mixed depressive and manic symptoms caused by volatile inhalant	Condition	SNOMED
mood_disorders	42538603	Mood disorder with manic symptoms caused by dissociative drug	Condition	SNOMED
mood_disorders	42538604	Mood disorder with depressive symptoms caused by dissociative drug	Condition	SNOMED
mood_disorders	42538605	Mood disorder with mixed depressive and manic symptoms caused by dissociative drug	Condition	SNOMED
mood_disorders	42538735	Mood disorder caused by synthetic cathinone	Condition	SNOMED
mood_disorders	42538736	Mood disorder with depressive symptoms caused by synthetic cathinone	Condition	SNOMED
mood_disorders	42538737	Mood disorder with manic symptoms caused by synthetic cathinone	Condition	SNOMED
mood_disorders	42539145	Mood disorder with manic symptoms caused by opioid	Condition	SNOMED
mood_disorders	42539371	Mood disorder with mixed depressive and manic symptoms caused by synthetic cathinone	Condition	SNOMED

mood_disorders	42872412	Severe mixed bipolar I disorder	Condition	SNOMED
mood_disorders	42872413	Severe depressed bipolar I disorder	Condition	SNOMED
mood_disorders	43020451	Severe manic bipolar I disorder	Condition	SNOMED
mood_disorders	43020483	Reactive depressive psychosis, single episode	Condition	SNOMED
mood_disorders	43021847	Rapid cycling bipolar I disorder	Condition	SNOMED
mood_disorders	43021849	Mood disorder of manic type	Condition	SNOMED
mood_disorders	44782518	Adjustment disorder with depressed mood in remission	Condition	SNOMED
mood_disorders	44782720	Severe seasonal affective disorder	Condition	SNOMED
mood_disorders	44782932	Cyclothymia in remission	Condition	SNOMED
mood_disorders	44782943	Depressive disorder in remission	Condition	SNOMED
mood_disorders	44784526	Adjustment disorder with anxious mood in remission	Condition	SNOMED
mood_disorders	44784632	Episodic mood disorder	Condition	SNOMED
mood_disorders	44804961	Mixed bipolar affective disorder, in partial remission	Condition	SNOMED
mood_disorders	44805540	Mixed bipolar affective disorder, severe	Condition	SNOMED
mood_disorders	44805543	Recurrent manic episodes, severe	Condition	SNOMED
mood_disorders	44805545	Single manic episode, severe	Condition	SNOMED
mood_disorders	44805547	Recurrent manic episodes, in partial remission	Condition	SNOMED
mood_disorders	44805548	Recurrent manic episodes, in remission	Condition	SNOMED
mood_disorders	44805552	Single manic episode in partial remission	Condition	SNOMED
mood_disorders	44805553	Single manic episode in remission	Condition	SNOMED
mood_disorders	45757195	Major depressive disorder in mother complicating childbirth	Condition	SNOMED
mood_disorders	45757196	Major depressive disorder in mother complicating pregnancy	Condition	SNOMED
mood_disorders	45757213	Depressive disorder in mother complicating childbirth	Condition	SNOMED
dementia	37312036	Aggression due to dementia	Condition	SNOMED
dementia	37312035	Agitation due to dementia	Condition	SNOMED
dementia	44784643	Altered behaviour in Alzheimer's disease	Condition	SNOMED
dementia	44784620	Altered behaviour in Huntington's dementia	Condition	SNOMED
dementia	378419	Alzheimer's disease	Condition	SNOMED
dementia	37395572	Alzheimer's disease co-occurrent with delirium	Condition	SNOMED
dementia	3654598	Amyotrophic lateral sclerosis, parkinsonism, dementia complex	Condition	SNOMED

dementia	4041685	Amyotrophic lateral sclerosis with dementia	Condition	SNOMED
dementia	37312031	Anxiety due to dementia	Condition	SNOMED
dementia	37312030	Apathetic behaviour due to dementia	Condition	SNOMED
dementia	376094	Arteriosclerotic dementia with delirium	Condition	SNOMED
dementia	374326	Arteriosclerotic dementia with depression	Condition	SNOMED
dementia	4100252	Arteriosclerotic dementia with paranoia	Condition	SNOMED
dementia	35608576	Behavioural and psychological symptoms of dementia	Condition	SNOMED
dementia	37117145	Behavioural disturbance co-occurrent and due to late onset Alzheimer dementia	Condition	SNOMED
dementia	37399020	Behavioural variant of frontotemporal dementia	Condition	SNOMED
dementia	4092747	Cerebral degeneration presenting primarily with dementia	Condition	SNOMED
dementia	45771254	CHMP2B-related frontotemporal dementia	Condition	SNOMED
dementia	3654434	Cortical vascular dementia	Condition	SNOMED
dementia	37111242	Delirium co-occurrent with dementia	Condition	SNOMED
dementia	44782726	Delusions in Alzheimer's disease	Condition	SNOMED
dementia	4182210	Dementia	Condition	SNOMED
dementia	4228133	Dementia associated with AIDS	Condition	SNOMED
dementia	378726	Dementia associated with alcoholism	Condition	SNOMED
dementia	374888	Dementia associated with another disease	Condition	SNOMED
dementia	44784607	Dementia associated with cerebral anoxia	Condition	SNOMED
dementia	44784472	Dementia associated with cerebral lipidosis	Condition	SNOMED
dementia	44784474	Dementia associated with multiple sclerosis	Condition	SNOMED
dementia	4314734	Dementia associated with Parkinson's Disease	Condition	SNOMED
dementia	37017549	Dementia co-occurrent with human immunodeficiency virus infection	Condition	SNOMED
dementia	36716797	Dementia due to chromosomal anomaly	Condition	SNOMED
dementia	4180284	Dementia due to Creutzfeldt Jakob disease	Condition	SNOMED
dementia	37110513	Dementia due to disorder of central nervous system	Condition	SNOMED
dementia	40483103	Dementia due to Huntington chorea	Condition	SNOMED

dementia	36716796	Dementia due to metabolic abnormality	Condition	SNOMED
dementia	44782559	Dementia due to multiple sclerosis with altered behaviour	Condition	SNOMED
dementia	44782422	Dementia due to Parkinson's disease	Condition	SNOMED
dementia	44782710	Dementia due to Pick's disease	Condition	SNOMED
dementia	42538609	Dementia due to prion disease	Condition	SNOMED
dementia	43020422	Dementia due to Rett's syndrome	Condition	SNOMED
dementia	441002	Dementia of frontal lobe type	Condition	SNOMED
dementia	43530664	Dementia of the Alzheimer type with behavioural disturbance	Condition	SNOMED
dementia	43530666	Dementia with behavioural disturbance	Condition	SNOMED
dementia	37116469	Dementia with Down syndrome	Condition	SNOMED
dementia	44782727	Depressed mood in Alzheimer's disease	Condition	SNOMED
dementia	4244346	Dialysis dementia	Condition	SNOMED
dementia	380701	Diffuse Lewy body disease	Condition	SNOMED
dementia	37311665	Disinhibited behaviour due to dementia	Condition	SNOMED
dementia	44782432	Early onset Alzheimer's disease with behavioural disturbance	Condition	SNOMED
dementia	37110677	Epilepsy co-occurrent and due to dementia	Condition	SNOMED
dementia	37018608	Epileptic dementia with behavioural disturbance	Condition	SNOMED
dementia	36717455	Familial Alzheimer-like prion disease	Condition	SNOMED
dementia	4043241	Familial Alzheimer's disease of early onset	Condition	SNOMED
dementia	4043243	Familial Alzheimer's disease of late onset	Condition	SNOMED
dementia	4043377	Focal Alzheimer's disease	Condition	SNOMED
dementia	4043378	Frontotemporal dementia	Condition	SNOMED
dementia	45765480	Frontotemporal dementia with parkinsonism-17	Condition	SNOMED
dementia	4250118	GDS level 4 - moderate cognitive decline	Condition	SNOMED
dementia	4233045	GDS level 5 - moderately severe cognitive decline	Condition	SNOMED
dementia	4236296	GDS level 6 - severe cognitive decline	Condition	SNOMED
dementia	4236297	GDS level 7 - very severe cognitive decline	Condition	SNOMED
dementia	45765477	GRN-related frontotemporal dementia	Condition	SNOMED
dementia	37109222	Hallucinations co-occurrent and due to late onset dementia	Condition	SNOMED

dementia	45766396	Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia	Condition	SNOMED
dementia	36717248	Ischemic vascular dementia	Condition	SNOMED
dementia	4044415	Language disorder of dementia	Condition	SNOMED
dementia	44782763	Lewy body dementia with behavioural disturbance	Condition	SNOMED
dementia	762497	Mild dementia	Condition	SNOMED
dementia	4046090	Mixed cortical and subcortical vascular dementia	Condition	SNOMED
dementia	43021816	Mixed dementia	Condition	SNOMED
dementia	762704	Moderate dementia	Condition	SNOMED
dementia	379778	Multi-infarct dementia	Condition	SNOMED
dementia	37395562	Multi-infarct dementia due to atherosclerosis	Condition	SNOMED
dementia	377254	Multi-infarct dementia, uncomplicated	Condition	SNOMED
dementia	444091	Multi-infarct dementia with delirium	Condition	SNOMED
dementia	443790	Multi-infarct dementia with delusions	Condition	SNOMED
dementia	443864	Multi-infarct dementia with depression	Condition	SNOMED
dementia	36716558	Non-amnesic Alzheimer disease	Condition	SNOMED
dementia	4043242	Non-familial Alzheimer's disease of early onset	Condition	SNOMED
dementia	4043244	Non-familial Alzheimer's disease of late onset	Condition	SNOMED
dementia	4224860	Organic dementia associated with AIDS	Condition	SNOMED
dementia	37396063	Parkinsonism with dementia of Guadeloupe	Condition	SNOMED
dementia	4047748	Patchy dementia	Condition	SNOMED
dementia	35610098	Predominantly cortical dementia	Condition	SNOMED
dementia	35610099	Predominantly cortical vascular dementia	Condition	SNOMED
dementia	378125	Presenile dementia	Condition	SNOMED
dementia	4224240	Presenile dementia associated with AIDS	Condition	SNOMED
dementia	37017247	Presenile dementia co-occurrent with human immunodeficiency virus infection	Condition	SNOMED
dementia	381832	Presenile dementia with delirium	Condition	SNOMED
dementia	44782771	Presenile dementia with delusions	Condition	SNOMED
dementia	377527	Presenile dementia with depression	Condition	SNOMED
dementia	4098163	Presenile dementia with paranoia	Condition	SNOMED
dementia	35610096	Presenile dementia with psychosis	Condition	SNOMED
dementia	43020444	Primary degenerative dementia	Condition	SNOMED

dementia	4218017	Primary degenerative dementia of the Alzheimer type, presenile onset	Condition	SNOMED
dementia	4277444	Primary degenerative dementia of the Alzheimer type, presenile onset, uncomplicated	Condition	SNOMED
dementia	4277746	Primary degenerative dementia of the Alzheimer type, presenile onset, with delirium	Condition	SNOMED
dementia	4182539	Primary degenerative dementia of the Alzheimer type, presenile onset, with delusions	Condition	SNOMED
dementia	4019705	Primary degenerative dementia of the Alzheimer type, presenile onset, with depression	Condition	SNOMED
dementia	4220313	Primary degenerative dementia of the Alzheimer type, senile onset	Condition	SNOMED
dementia	4278830	Primary degenerative dementia of the Alzheimer type, senile onset, uncomplicated	Condition	SNOMED
dementia	762578	Primary degenerative dementia of the Alzheimer type, senile onset, with behavioural disturbance	Condition	SNOMED
dementia	4167839	Primary degenerative dementia of the Alzheimer type, senile onset, with delirium	Condition	SNOMED
dementia	4204688	Primary degenerative dementia of the Alzheimer type, senile onset, with delusions	Condition	SNOMED
dementia	4097384	Primary degenerative dementia of the Alzheimer type, senile onset, with depression	Condition	SNOMED
dementia	36674472	PRKAR1B-related neurodegenerative dementia with intermediate filaments	Condition	SNOMED
dementia	4043379	Progressive aphasia in Alzheimer's disease	Condition	SNOMED
dementia	37311890	Psychological symptom due to dementia	Condition	SNOMED
dementia	37109635	Rapidly progressive dementia	Condition	SNOMED
dementia	4046091	Semantic dementia	Condition	SNOMED
dementia	4048875	Senile dementia	Condition	SNOMED
dementia	4196433	Senile dementia of the Lewy body type	Condition	SNOMED
dementia	376946	Senile dementia with delirium	Condition	SNOMED
dementia	380986	Senile dementia with delusion	Condition	SNOMED
dementia	379784	Senile dementia with depression	Condition	SNOMED
dementia	4101137	Senile dementia with depressive or paranoid features	Condition	SNOMED
dementia	4100250	Senile dementia with paranoia	Condition	SNOMED
dementia	4159643	Senile dementia with psychosis	Condition	SNOMED

dementia	765653	Severe dementia	Condition	SNOMED
dementia	42538857	Subcortical dementia	Condition	SNOMED
dementia	4047747	Subcortical vascular dementia	Condition	SNOMED
dementia	439276	Uncomplicated arteriosclerotic dementia	Condition	SNOMED
dementia	376085	Uncomplicated presenile dementia	Condition	SNOMED
dementia	375791	Uncomplicated senile dementia	Condition	SNOMED
dementia	443605	Vascular dementia	Condition	SNOMED
dementia	4046089	Vascular dementia of acute onset	Condition	SNOMED
dementia	37018688	Vascular dementia with behavioural disturbance	Condition	SNOMED
dementia	37109056	Vascular dementia without behavioural disturbance	Condition	SNOMED
dementia	37312577	Wandering due to dementia	Condition	SNOMED
apathy	4071366	Indifference	Condition	SNOMED
apathy	37312030	Apathetic behaviour due to dementia	Condition	SNOMED
intellectual_disability	40277917	Intellectual disability	Condition	SNOMED
intellectual_disability	608002	X-linked intellectual disability hypotonic face syndrome	Condition	SNOMED
intellectual_disability	4041136	Intellectual functioning disability	Condition	SNOMED
intellectual_disability	438733	Profound intellectual disability	Condition	SNOMED
intellectual_disability	4141891	Hyperphosphatasaemia with intellectual disability	Condition	SNOMED
intellectual_disability	432898	Severe intellectual disability	Condition	SNOMED
intellectual_disability	4133527	Intellectual disability, congenital heart disease, blepharophimosis, blepharoptosis and hypoplastic teeth	Condition	SNOMED
intellectual_disability	4173610	X-linked intellectual disability with marfanoid habitus	Condition	SNOMED
intellectual_disability	436682	Moderate intellectual disability	Condition	SNOMED
intellectual_disability	45766270	CASK related intellectual disability	Condition	SNOMED
intellectual_disability	37399441	Alpha thalassemia X-linked intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37399497	Early onset parkinsonism and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37396778	Female restricted epilepsy with intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37399013	FRAXE intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37397173	Microphthalmia with ankyloblepharon and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36713803	Spondyloepiphyseal dysplasia, craniosynostosis, cleft palate, cataract, and intellectual disability syndrome	Condition	SNOMED

intellectual_disability	36713853	X-linked intellectual disability with ataxia and apraxia syndrome	Condition	SNOMED
intellectual_disability	36717325	X-linked recessive intellectual disability and macrocephaly with ciliary dysfunction syndrome	Condition	SNOMED
intellectual_disability	36717679	X-linked intellectual disability Seemanova type	Condition	SNOMED
intellectual_disability	36713896	Syndromic X-linked intellectual disability type 11	Condition	SNOMED
intellectual_disability	36713900	X-linked intellectual disability Shrimpton type	Condition	SNOMED
intellectual_disability	36713902	X-linked intellectual disability Siderius type	Condition	SNOMED
intellectual_disability	36713903	X-linked intellectual disability Stevenson type	Condition	SNOMED
intellectual_disability	36713904	X-linked intellectual disability Stocco Dos Santos type	Condition	SNOMED
intellectual_disability	36713905	X-linked intellectual disability Stoll type	Condition	SNOMED
intellectual_disability	36713906	X-linked intellectual disability Turner type	Condition	SNOMED
intellectual_disability	36713908	X-linked intellectual disability Van Esch type	Condition	SNOMED
intellectual_disability	36717686	X-linked intellectual disability Wilson type	Condition	SNOMED
intellectual_disability	36713963	X-linked intellectual disability Schimke type	Condition	SNOMED
intellectual_disability	36713964	X-linked intellectual disability Pai type	Condition	SNOMED
intellectual_disability	36713965	X-linked intellectual disability Miles Carpenter type	Condition	SNOMED
intellectual_disability	36713966	X-linked intellectual disability Cilliers type	Condition	SNOMED
intellectual_disability	36713967	X-linked intellectual disability Cantagrel type	Condition	SNOMED
intellectual_disability	36713968	X-linked intellectual disability Armfield type	Condition	SNOMED
intellectual_disability	36713969	X-linked intellectual disability Abidi type	Condition	SNOMED
intellectual_disability	36713988	Uveal coloboma with cleft lip and palate and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36714051	X-linked intellectual disability with cerebellar hypoplasia syndrome	Condition	SNOMED
intellectual_disability	36714053	X-linked intellectual disability with cubitus valgus and dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36714067	X-linked intellectual disability and epilepsy with progressive joint	Condition	SNOMED

		contracture and facial dysmorphism syndrome		
intellectual_disability	36714068	X-linked intellectual disability with hypogammaglobulinemia and progressive neurological deterioration syndrome	Condition	SNOMED
intellectual_disability	36714069	X-linked intellectual disability and hypotonia with facial dysmorphism and aggressive behaviour syndrome	Condition	SNOMED
intellectual_disability	36714072	Syndromic X-linked intellectual disability type 7	Condition	SNOMED
intellectual_disability	36714073	Syndromic X-linked intellectual disability due to JARID1C mutation	Condition	SNOMED
intellectual_disability	36714144	Pterygium colli with intellectual disability and digital anomaly syndrome	Condition	SNOMED
intellectual_disability	36714286	Disorder of sex development with intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36714528	X-linked intellectual disability with seizure and psoriasis syndrome	Condition	SNOMED
intellectual_disability	36714529	X-linked intellectual disability Cabezas type	Condition	SNOMED
intellectual_disability	36717758	X-linked intellectual disability with plagiocephaly syndrome	Condition	SNOMED
intellectual_disability	36714541	X-linked intellectual disability, macrocephaly, macroorchidism syndrome	Condition	SNOMED
intellectual_disability	36714542	X-linked intellectual disability with acromegaly and hyperactivity syndrome	Condition	SNOMED
intellectual_disability	36714554	Congenital hypoplasia of ulna and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715012	Aniridia and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715036	Arachnodactyly with abnormal ossification and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715037	Arachnodactyly and intellectual disability with facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36715050	Ataxia with deafness and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715141	Coloboma, congenital heart disease, ichthyosiform dermatosis, intellectual disability ear anomaly syndrome	Condition	SNOMED
intellectual_disability	36717431	Alopecia, contracture, dwarfism, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715349	Alopecia, psychomotor epilepsy, periodontal pyorrhea, intellectual disability syndrome	Condition	SNOMED

intellectual_disability	36715350	Alopecia and intellectual disability with hypergonadotropic hypogonadism syndrome	Condition	SNOMED
intellectual_disability	36715351	Alport syndrome, intellectual disability, midface hypoplasia, elliptocytosis syndrome	Condition	SNOMED
intellectual_disability	36715355	Aniridia, ptosis, intellectual disability, familial obesity syndrome	Condition	SNOMED
intellectual_disability	36715367	Hair defect with photosensitivity and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715416	Deafness and intellectual disability Martin Probst type syndrome	Condition	SNOMED
intellectual_disability	36717441	Dentinogenesis imperfecta, short stature, hearing loss, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36715461	Intellectual disability, epilepsy, bulbous nose syndrome	Condition	SNOMED
intellectual_disability	36715509	Seizure, sensorineural deafness, ataxia, intellectual disability, electrolyte imbalance syndrome	Condition	SNOMED
intellectual_disability	36716030	Hypogonadism with mitral valve prolapse and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36716108	Lipodystrophy, intellectual disability, deafness syndrome	Condition	SNOMED
intellectual_disability	36716124	Intellectual disability with cataract and kyphosis syndrome	Condition	SNOMED
intellectual_disability	36716191	Osteogenesis imperfecta, retinopathy, seizures, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36716192	Osteopenia, myopia, hearing loss, intellectual disability, facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36716260	Spastic paraplegia, intellectual disability, palmoplantar hyperkeratosis syndrome	Condition	SNOMED
intellectual_disability	36716264	Severe X-linked intellectual disability Gustavson type	Condition	SNOMED
intellectual_disability	36717547	Agenesis of corpus callosum, intellectual disability, coloboma, micrognathia syndrome	Condition	SNOMED
intellectual_disability	36716388	Congenital cataract with hypertrichosis and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36717215	Intellectual disability, craniofacial dysmorphism, hypogonadism, diabetes mellitus syndrome	Condition	SNOMED
intellectual_disability	36716446	Intellectual disability, hypoplastic corpus callosum, preauricular tag syndrome	Condition	SNOMED

intellectual_disability	36716447	Intellectual disability, developmental delay, contracture syndrome	Condition	SNOMED
intellectual_disability	36716449	Male hypergonadotropic hypogonadism, intellectual disability, skeletal anomaly syndrome	Condition	SNOMED
intellectual_disability	36716463	Skeletal dysplasia with intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37118888	Microcephaly, seizure, intellectual disability, heart disease syndrome	Condition	SNOMED
intellectual_disability	37109597	Fallot complex with intellectual disability and growth delay syndrome	Condition	SNOMED
intellectual_disability	37109617	Hypotrichosis and intellectual disability syndrome Lopes type	Condition	SNOMED
intellectual_disability	37118953	Non-progressive cerebellar ataxia with intellectual disability	Condition	SNOMED
intellectual_disability	37109775	Spastic tetraplegia, retinitis pigmentosa, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37118973	Severe intellectual disability, epilepsy, anal anomaly, distal phalangeal hypoplasia syndrome	Condition	SNOMED
intellectual_disability	37109991	Seizures and intellectual disability due to hydroxylysineuria	Condition	SNOMED
intellectual_disability	37109996	Retinitis pigmentosa, intellectual disability, deafness, hypogenitalism syndrome	Condition	SNOMED
intellectual_disability	37110103	Laryngeal abductor paralysis with intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37110783	X-linked spasticity, intellectual disability, epilepsy syndrome	Condition	SNOMED
intellectual_disability	37111245	Intellectual disability Buenos Aires type	Condition	SNOMED
intellectual_disability	37111251	X-linked intellectual disability Brooks type	Condition	SNOMED
intellectual_disability	37111654	Intellectual disability, cataract, calcified pinna, myopathy syndrome	Condition	SNOMED
intellectual_disability	37111663	X-linked intellectual disability Hedera type	Condition	SNOMED
intellectual_disability	37111667	X-linked intellectual disability Nascimento type	Condition	SNOMED
intellectual_disability	37115758	X-linked intellectual disability, limb spasticity, retinal dystrophy, diabetes insipidus syndrome	Condition	SNOMED
intellectual_disability	37118457	Cortical blindness, intellectual disability, polydactyly syndrome	Condition	SNOMED
intellectual_disability	37117739	Osteopenia, intellectual disability, sparse hair syndrome	Condition	SNOMED
intellectual_disability	37116296	Branchial dysplasia, intellectual disability, inguinal hernia syndrome	Condition	SNOMED

intellectual_disability	37116372	Marfanoid habitus with autosomal recessive intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37116391	Preaxial polydactyly, colobomata, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37116399	Ichthyosis, intellectual disability, dwarfism, renal impairment syndrome	Condition	SNOMED
intellectual_disability	37116413	Thumb stiffness, brachydactyly, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37116641	Metaphyseal dysostosis, intellectual disability, conductive deafness syndrome	Condition	SNOMED
intellectual_disability	37116656	Spastic paraplegia, glaucoma, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37116668	Hereditary congenital hypomelanotic and hypermelanotic cutaneous macules, growth retardation, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37116706	Megalocornea with intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37118763	Ectodermal dysplasia, intellectual disability, central nervous system malformation syndrome	Condition	SNOMED
intellectual_disability	42539413	Alpha-thalassemia intellectual disability syndrome linked to chromosome 16	Condition	SNOMED
intellectual_disability	35621875	Charcot-Marie-Tooth disease, deafness, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	35622032	Cerebellar ataxia, intellectual disability, oculomotor apraxia, cerebellar cysts syndrome	Condition	SNOMED
intellectual_disability	35622038	Intellectual disability, obesity, brain malformation, facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	35622087	Ichthyosis, alopecia, eclabion, ectropion, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	35622247	Aortic arch anomaly, facial dysmorphism, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	35622258	Intellectual disability due to nutritional deficiency	Condition	SNOMED
intellectual_disability	35622278	Craniodigital syndrome and intellectual disability syndrome	Condition	SNOMED
intellectual_disability	35622323	Intellectual disability, alacrima, achalasia syndrome	Condition	SNOMED
intellectual_disability	35622324	Intellectual disability, polydactyly, uncombable hair syndrome	Condition	SNOMED
intellectual_disability	35622325	Intellectual disability, spasticity, ectrodactyly syndrome	Condition	SNOMED

intellectual_disability	35622326	Intellectual disability, brachydactyly, Pierre Robin syndrome	Condition	SNOMED
intellectual_disability	35622327	Intellectual disability Wolff type	Condition	SNOMED
intellectual_disability	35607971	Pachygyria, intellectual disability, epilepsy syndrome	Condition	SNOMED
intellectual_disability	35622702	Intellectual disability Birk-Barel type	Condition	SNOMED
intellectual_disability	35622769	Cryptorchidism, arachnodactyly, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	35622777	Intellectual disability, myopathy, short stature, endocrine defect syndrome	Condition	SNOMED
intellectual_disability	35622869	Focal epilepsy, intellectual disability, cerebro-cerebellar malformation syndrome	Condition	SNOMED
intellectual_disability	35623128	HIVEP2-related intellectual disability	Condition	SNOMED
intellectual_disability	35623139	X-linked intellectual disability, hypogonadism, ichthyosis, obesity, short stature syndrome	Condition	SNOMED
intellectual_disability	35623289	Brachydactyly, mesomelia, intellectual disability, heart defect syndrome	Condition	SNOMED
intellectual_disability	35624210	ADNP-related multiple congenital anomalies, intellectual disability, autism spectrum disorder	Condition	SNOMED
intellectual_disability	35625633	PPP2R5D-related intellectual disability	Condition	SNOMED
intellectual_disability	36674712	Early-onset epileptic encephalopathy and intellectual disability due to GRIN2A mutation	Condition	SNOMED
intellectual_disability	36674826	Polyneuropathy, intellectual disability, acromicria, premature menopause syndrome	Condition	SNOMED
intellectual_disability	36674865	Microcephaly, thin corpus callosum, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36674867	Optic atrophy, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36674893	Intellectual disability, seizures, macrocephaly, obesity syndrome	Condition	SNOMED
intellectual_disability	36674191	Intellectual disability, seizures, hypotonia, ophthalmologic, skeletal anomalies syndrome	Condition	SNOMED
intellectual_disability	36674914	Autosomal recessive cerebellar ataxia, epilepsy, intellectual disability syndrome due to WWOX deficiency	Condition	SNOMED
intellectual_disability	36674915	Autosomal recessive intellectual disability, motor dysfunction, multiple joint contracture syndrome	Condition	SNOMED
intellectual_disability	36674971	Microcephaly, short stature, intellectual disability, facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36674974	Intellectual disability, short stature, hypertelorism syndrome	Condition	SNOMED

intellectual_disability	36674995	X-linked colobomatous microphthalmia, microcephaly, intellectual disability, short stature syndrome	Condition	SNOMED
intellectual_disability	36674996	Hepatic fibrosis, renal cyst, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	4299505	Borderline intellectual disability	Condition	SNOMED
intellectual_disability	36676400	X-linked intellectual disability, craniofacioskeletal syndrome	Condition	SNOMED
intellectual_disability	36676502	Intellectual disability with strabismus syndrome	Condition	SNOMED
intellectual_disability	36676513	Intellectual disability, facial dysmorphism, hand anomalies syndrome	Condition	SNOMED
intellectual_disability	36676516	Severe intellectual disability, short stature, behavioural abnormalities, facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36676588	Autosomal recessive cerebellar ataxia, epilepsy, intellectual disability syndrome due to TUD deficiency	Condition	SNOMED
intellectual_disability	36676621	Early-onset epileptic encephalopathy, cortical blindness, intellectual disability, facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36676624	Severe intellectual disability, poor language, strabismus, grimacing face, long fingers syndrome	Condition	SNOMED
intellectual_disability	36676625	Intellectual disability, feeding difficulties, developmental delay, microcephaly syndrome	Condition	SNOMED
intellectual_disability	36676626	Hypohidrosis, enamel hypoplasia, palmoplantar keratoderma, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36676629	Short ulna, dysmorphism, hypotonia, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36676634	Spondylocostal dysostosis, hypospadias, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36676637	Intellectual disability, craniofacial dysmorphism, cryptorchidism syndrome	Condition	SNOMED
intellectual_disability	36676639	Aphonia, deafness, retinal dystrophy, bifid halluces, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36676642	X-linked intellectual disability, cardiomegaly, congestive heart failure syndrome	Condition	SNOMED
intellectual_disability	36676669	Intellectual disability, hypotonia, brachycephaly, pyloric stenosis, cryptorchidism syndrome	Condition	SNOMED

intellectual_disability	36676715	Late-onset localized junctional epidermolysis bullosa, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36676726	Rare non-syndromic intellectual disability	Condition	SNOMED
intellectual_disability	36674471	AHDC1-related intellectual disability, obstructive sleep apnoea, mild dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36674490	Intellectual disability, obesity, prognathism, eye and skin anomalies syndrome	Condition	SNOMED
intellectual_disability	36676854	Severe intellectual disability, progressive postnatal microcephaly, midline stereotypic hand movements syndrome	Condition	SNOMED
intellectual_disability	36676897	Intellectual disability, severe speech delay, mild dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36678790	Colobomatous microphthalmia, obesity, hypogenitalism, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	36680587	Blepharophimosis, intellectual disability syndrome, Verloes type	Condition	SNOMED
intellectual_disability	36674508	Severe intellectual disability and progressive spastic paraplegia	Condition	SNOMED
intellectual_disability	36683256	SYNGAP1-related intellectual disability	Condition	SNOMED
intellectual_disability	37204209	Autosomal recessive cerebellar ataxia, epilepsy, intellectual disability syndrome due to RUBCN deficiency	Condition	SNOMED
intellectual_disability	37204211	Severe intellectual disability, progressive spastic diplegia syndrome	Condition	SNOMED
intellectual_disability	37204216	Intellectual disability, facial dysmorphism syndrome due to SETD5 haploinsufficiency	Condition	SNOMED
intellectual_disability	37204230	Intellectual disability, coarse face, macrocephaly, cerebellar hypotrophy syndrome	Condition	SNOMED
intellectual_disability	37204232	Primary microcephaly, mild intellectual disability, young-onset diabetes syndrome	Condition	SNOMED
intellectual_disability	37204238	Congenital muscular dystrophy with intellectual disability and severe epilepsy	Condition	SNOMED
intellectual_disability	37204321	Ophthalmoplegia, intellectual disability, lingua scrotalis syndrome	Condition	SNOMED
intellectual_disability	37204364	Severe microbrachycephaly, intellectual disability, athetoid cerebral palsy syndrome	Condition	SNOMED
intellectual_disability	37204430	Macrocephaly, intellectual disability, autism syndrome	Condition	SNOMED

intellectual_disability	37204504	Congenital muscular dystrophy with intellectual disability	Condition	SNOMED
intellectual_disability	37204505	Congenital muscular dystrophy without intellectual disability	Condition	SNOMED
intellectual_disability	37204735	DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion	Condition	SNOMED
intellectual_disability	37204804	X-linked intellectual disability due to GRIA3 mutations	Condition	SNOMED
intellectual_disability	37204805	White matter hypoplasia, corpus callosum agenesis, intellectual disability syndrome	Condition	SNOMED
intellectual_disability	37206827	Intellectual disability, hyperkinetic movement, truncal ataxia syndrome	Condition	SNOMED
intellectual_disability	37206828	ANK3-related intellectual disability, sleep disturbance syndrome	Condition	SNOMED
intellectual_disability	37312387	Alopecia, epilepsy, intellectual disability syndrome Moynahan type	Condition	SNOMED
intellectual_disability	432612	Mild intellectual disability	Condition	SNOMED
intellectual_disability	436803	Fragile X syndrome	Condition	SNOMED
intellectual_disability	37204317	Richieri Costa-da Silva syndrome	Condition	SNOMED
intellectual_disability	35610128	Mild intellectual development disorder with minimal impairment of behaviour	Condition	SNOMED
intellectual_disability	36714026	Congenital cataract with ataxia and deafness syndrome	Condition	SNOMED
intellectual_disability	36717662	Oro-facial digital syndrome type 11	Condition	SNOMED
intellectual_disability	36716189	Ossification anomaly with psychomotor developmental delay syndrome	Condition	SNOMED
intellectual_disability	35610115	Profound intellectual development disorder with significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36717691	Shprintzen Goldberg craniosynostosis syndrome	Condition	SNOMED
intellectual_disability	36674921	Kagami Ogata syndrome	Condition	SNOMED
intellectual_disability	45765422	PPM-X syndrome	Condition	SNOMED
intellectual_disability	37117794	SCARF syndrome	Condition	SNOMED
intellectual_disability	36713856	Fried syndrome	Condition	SNOMED
intellectual_disability	35610117	Profound intellectual development disorder with impairment of behaviour	Condition	SNOMED
intellectual_disability	35610118	Severe intellectual development disorder without significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36716048	Radioulnar synostosis with developmental delay and hypotonia syndrome	Condition	SNOMED
intellectual_disability	37397559	Wolf Hirschhorn syndrome	Condition	SNOMED

intellectual_disability	36714074	Radioulnar synostosis with microcephaly and scoliosis syndrome	Condition	SNOMED
intellectual_disability	36714383	17q11.2 microduplication syndrome	Condition	SNOMED
intellectual_disability	36714522	DOORS syndrome	Condition	SNOMED
intellectual_disability	36717524	MEDNIK syndrome	Condition	SNOMED
intellectual_disability	37116354	Epilepsy, microcephaly, skeletal dysplasia syndrome	Condition	SNOMED
intellectual_disability	37206121	Hyperekplexia epilepsy syndrome	Condition	SNOMED
intellectual_disability	4296631	Angelman syndrome	Condition	SNOMED
intellectual_disability	35607964	Agenesis of corpus callosum and abnormal genitalia syndrome	Condition	SNOMED
intellectual_disability	36675149	15q overgrowth syndrome	Condition	SNOMED
intellectual_disability	36676500	Severe feeding difficulties, failure to thrive, microcephaly due to ASXL3 deficiency syndrome	Condition	SNOMED
intellectual_disability	36715217	Cooper Jabs syndrome	Condition	SNOMED
intellectual_disability	35610518	Intellectual development disorder with significant impairment of behaviour	Condition	SNOMED
intellectual_disability	37116639	Facial dysmorphism, macrocephaly, myopia, Dandy-Walker malformation syndrome	Condition	SNOMED
intellectual_disability	36716389	Martsolf syndrome	Condition	SNOMED
intellectual_disability	35610519	Intellectual development disorder with minimal impairment of behaviour	Condition	SNOMED
intellectual_disability	45765412	Pitt-Hopkins syndrome	Condition	SNOMED
intellectual_disability	36713570	BRESEK syndrome	Condition	SNOMED
intellectual_disability	36675122	Autism epilepsy syndrome due to branched chain ketoacid dehydrogenase kinase deficiency	Condition	SNOMED
intellectual_disability	36716314	Agammaglobulinemia, microcephaly, craniosynostosis, severe dermatitis syndrome	Condition	SNOMED
intellectual_disability	36715305	Cerebrooculonasal syndrome	Condition	SNOMED
intellectual_disability	36674736	Microcephalic primordial dwarfism Dauber type	Condition	SNOMED
intellectual_disability	37110832	5-amino-4-imidazole carboxamide ribosiduria	Condition	SNOMED
intellectual_disability	35610119	Severe intellectual development disorder with significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36676627	THOC6-related developmental delay-microcephaly-facial dysmorphism syndrome	Condition	SNOMED
intellectual_disability	37109595	Faciocardiorenal syndrome	Condition	SNOMED
intellectual_disability	37110134	Infantile choroidocerebral calcification syndrome	Condition	SNOMED

intellectual_disability	36716160	Okamoto syndrome	Condition	SNOMED
intellectual_disability	35623414	Microcephalic primordial dwarfism Montreal type	Condition	SNOMED
intellectual_disability	37116412	Aniridia, renal agenesis, psychomotor retardation syndrome	Condition	SNOMED
intellectual_disability	35624222	Epiphyseal dysplasia, hearing loss, dysmorphism syndrome	Condition	SNOMED
intellectual_disability	36715332	Fine Lubinsky syndrome	Condition	SNOMED
intellectual_disability	35621977	Facial dysmorphism, cleft palate, loose skin syndrome	Condition	SNOMED
intellectual_disability	44783252	Myhre syndrome	Condition	SNOMED
intellectual_disability	37396341	Kawashima Tsuji syndrome	Condition	SNOMED
intellectual_disability	35625760	DNMT3A-related overgrowth syndrome	Condition	SNOMED
intellectual_disability	36675177	Autism spectrum disorder due to AUTS2 deficiency	Condition	SNOMED
intellectual_disability	36675142	Jawad syndrome	Condition	SNOMED
intellectual_disability	35610122	Moderate intellectual development disorder without significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36716387	Congenital cataract with deafness and hypogonadism syndrome	Condition	SNOMED
intellectual_disability	4033911	Kohlschutter's syndrome	Condition	SNOMED
intellectual_disability	3657468	Significant learning disability	Condition	SNOMED
intellectual_disability	44783569	Renpenning syndrome	Condition	SNOMED
intellectual_disability	35610123	Moderate intellectual development disorder with significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36676583	9q31.1q31.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	36674903	Developmental delay with autism spectrum disorder and gait instability	Condition	SNOMED
intellectual_disability	35622011	Craniofaciofrontodigital syndrome	Condition	SNOMED
intellectual_disability	4072144	Cross syndrome	Condition	SNOMED
intellectual_disability	36713523	Biemond syndrome type 2	Condition	SNOMED
intellectual_disability	35610127	Mild intellectual development disorder with significant impairment of behaviour	Condition	SNOMED
intellectual_disability	35621906	Grubben, De Cock, Borghgraef syndrome	Condition	SNOMED
intellectual_disability	4288480	Rett's disorder	Condition	SNOMED
intellectual_disability	36674517	Atypical hypotonia cystinuria syndrome	Condition	SNOMED
intellectual_disability	36715139	Cerebro-facio-thoracic dysplasia	Condition	SNOMED
intellectual_disability	35622041	Cerebrofacioarticular syndrome	Condition	SNOMED
intellectual_disability	36713991	12q14 microdeletion syndrome	Condition	SNOMED

intellectual_disability	37110772	Temple Baraitser syndrome	Condition	SNOMED
intellectual_disability	37395856	McDonough syndrome	Condition	SNOMED
intellectual_disability	37118960	Ramos Arroyo syndrome	Condition	SNOMED
intellectual_disability	37396500	Urban Rogers Meyer syndrome	Condition	SNOMED
intellectual_disability	36674770	X-linked cerebral, cerebellar, coloboma syndrome	Condition	SNOMED
intellectual_disability	36713653	Atkin Flaitz syndrome	Condition	SNOMED
intellectual_disability	36715331	Filippi syndrome	Condition	SNOMED
intellectual_disability	36714301	Cleft palate with short stature and vertebral anomaly syndrome	Condition	SNOMED
intellectual_disability	45765468	Snyder-Robinson syndrome	Condition	SNOMED
intellectual_disability	36676430	Zechi Ceide syndrome	Condition	SNOMED
intellectual_disability	35610120	Severe intellectual development disorder with minimal impairment of behaviour	Condition	SNOMED
intellectual_disability	36675667	White Sutton syndrome	Condition	SNOMED
intellectual_disability	37111628	Weaver Williams syndrome	Condition	SNOMED
intellectual_disability	36716154	Oculocerebrofacial syndrome Kaufman type	Condition	SNOMED
intellectual_disability	44783239	Ohdo syndrome, Say-Barber-Biesecker-Young-Simpson variant	Condition	SNOMED
intellectual_disability	37204024	Developmental delay, facial dysmorphism syndrome due to MED13L deficiency	Condition	SNOMED
intellectual_disability	35610516	Mild intellectual development disorder with impairment of behaviour	Condition	SNOMED
intellectual_disability	605204	X-linked complicated corpus callosum dysgenesis	Condition	SNOMED
intellectual_disability	4209284	Bardet-Biedl syndrome	Condition	SNOMED
intellectual_disability	35610520	Intellectual development disorder with impairment of behaviour	Condition	SNOMED
intellectual_disability	36674396	Deafness with onychodystrophy syndrome	Condition	SNOMED
intellectual_disability	37204308	Hereditary cryohydrocytosis with reduced stomatin	Condition	SNOMED
intellectual_disability	4100702	Gillespie syndrome	Condition	SNOMED
intellectual_disability	4065596	Borjeson-Forssman-Lehmann syndrome	Condition	SNOMED
intellectual_disability	35607999	Cognitive impairment, coarse facies, heart defects, obesity, pulmonary involvement, short stature, skeletal dysplasia syndrome	Condition	SNOMED
intellectual_disability	36714103	Spondyloepiphyseal dysplasia tarda Kohn type	Condition	SNOMED
intellectual_disability	4240091	Seckel syndrome	Condition	SNOMED

intellectual_disability	37396390	Perniola Krajewska Carnevale syndrome	Condition	SNOMED
intellectual_disability	37109675	Phosphoribosylpyrophosphate synthetase superactivity	Condition	SNOMED
intellectual_disability	35610116	Profound intellectual development disorder with minimal impairment of behaviour	Condition	SNOMED
intellectual_disability	37206825	21q22.11q22.12 microdeletion syndrome	Condition	SNOMED
intellectual_disability	37116293	Brachydactyly and preaxial hallux varus syndrome	Condition	SNOMED
intellectual_disability	36675025	Pseudoleprechaunism syndrome Patterson type	Condition	SNOMED
intellectual_disability	35624153	Nijmegen breakage syndrome-like disorder	Condition	SNOMED
intellectual_disability	45766388	Mowat-Wilson syndrome	Condition	SNOMED
intellectual_disability	45765490	Arts syndrome	Condition	SNOMED
intellectual_disability	36675005	Extrasystoles, short stature, hyperpigmentation, microcephaly syndrome	Condition	SNOMED
intellectual_disability	36676696	Distal Xq28 microduplication syndrome	Condition	SNOMED
intellectual_disability	37312299	Blepharophimosis and mental retardation syndrome	Condition	SNOMED
intellectual_disability	35622341	Macrocephaly and developmental delay syndrome	Condition	SNOMED
intellectual_disability	36676367	Cyclin-dependent kinase-like 5 deficiency	Condition	SNOMED
intellectual_disability	37111247	Neurofaciodigitorenal syndrome	Condition	SNOMED
intellectual_disability	45771339	Neuronal ceroid lipofuscinosis 8	Condition	SNOMED
intellectual_disability	36717050	Achalasia microcephaly syndrome	Condition	SNOMED
intellectual_disability	36674894	Severe motor and intellectual disabilities, sensorineural deafness, dystonia syndrome	Condition	SNOMED
intellectual_disability	36674906	5p13 microduplication syndrome	Condition	SNOMED
intellectual_disability	37395980	MORM syndrome	Condition	SNOMED
intellectual_disability	36674735	Microcephalic primordial dwarfism Alazami type	Condition	SNOMED
intellectual_disability	37396321	Harrod syndrome	Condition	SNOMED
intellectual_disability	37111630	Short stature, unique facies, enamel hypoplasia, progressive joint stiffness, high-pitched voice syndrome	Condition	SNOMED
intellectual_disability	37398922	Skeletal dysplasia with epilepsy and short stature syndrome	Condition	SNOMED
intellectual_disability	36714548	Wilson Turner syndrome	Condition	SNOMED
intellectual_disability	37396327	Goldblatt Wallis syndrome	Condition	SNOMED

intellectual_disability	36714238	Microcephalus with brachydactyly and kyphoscoliosis syndrome	Condition	SNOMED
intellectual_disability	36716462	Toriello Carey syndrome	Condition	SNOMED
intellectual_disability	36717687	Pallister W syndrome	Condition	SNOMED
intellectual_disability	36716139	Kapur Toriello syndrome	Condition	SNOMED
intellectual_disability	37116407	Van den Bosch syndrome	Condition	SNOMED
intellectual_disability	37110119	Kleefstra syndrome	Condition	SNOMED
intellectual_disability	37111590	Caudal appendage deafness syndrome	Condition	SNOMED
intellectual_disability	37111627	Central nervous system calcification, deafness, tubular acidosis, anaemia syndrome	Condition	SNOMED
intellectual_disability	36717046	Blepharonasofacial malformation syndrome	Condition	SNOMED
intellectual_disability	36675714	Warburg micro syndrome	Condition	SNOMED
intellectual_disability	36676440	CK syndrome	Condition	SNOMED
intellectual_disability	36717424	Cystic leukoencephalopathy without megalencephaly	Condition	SNOMED
intellectual_disability	35610125	Moderate intellectual development disorder with impairment of behaviour	Condition	SNOMED
intellectual_disability	36717734	1p21.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	36715216	Contracture with ectodermal dysplasia and orofacial cleft syndrome	Condition	SNOMED
intellectual_disability	37204408	Facial dysmorphism, developmental delay, behavioural abnormalities syndrome due to 10p11.21p12.31 microdeletion	Condition	SNOMED
intellectual_disability	36680576	Temtamy preaxial brachydactyly syndrome	Condition	SNOMED
intellectual_disability	36716187	Oro-facial digital syndrome type 5	Condition	SNOMED
intellectual_disability	36716188	Oro-facial digital syndrome type 8	Condition	SNOMED
intellectual_disability	37397118	Trisomy 10p	Condition	SNOMED
intellectual_disability	36717698	Prieto Badia Mulas syndrome	Condition	SNOMED
intellectual_disability	36675144	Developmental and speech delay due to SOX5 deficiency	Condition	SNOMED
intellectual_disability	36676426	Spondyloepimetaphyseal dysplasia Genevieve type	Condition	SNOMED
intellectual_disability	36674461	Piebald trait with neurologic defects syndrome	Condition	SNOMED
intellectual_disability	36716109	Lowry MacLean syndrome	Condition	SNOMED
intellectual_disability	37116355	Epilepsy telangiectasia syndrome	Condition	SNOMED
intellectual_disability	4332239	Savant syndrome	Condition	SNOMED
intellectual_disability	604335	14q32 deletion syndrome	Condition	SNOMED
intellectual_disability	36675148	Autosomal recessive leukoencephalopathy, ischemic stroke, retinitis pigmentosa syndrome	Condition	SNOMED

intellectual_disability	36716141	Macrocephaly, short stature, paraplegia syndrome	Condition	SNOMED
intellectual_disability	4241107	Cutis laxa-corneal clouding-oligophrenia syndrome	Condition	SNOMED
intellectual_disability	3654718	MASA syndrome	Condition	SNOMED
intellectual_disability	37116365	Encephalopathy, intracerebral calcification, retinal degeneration syndrome	Condition	SNOMED
intellectual_disability	36714240	Microcephalus cardiomyopathy syndrome	Condition	SNOMED
intellectual_disability	36713733	Oro-facial digital syndrome type 9	Condition	SNOMED
intellectual_disability	37110022	Psychomotor retardation due to S-adenosylhomocysteine hydrolase deficiency	Condition	SNOMED
intellectual_disability	36676620	13q12.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	35610126	Mild intellectual development disorder without significant impairment of behaviour	Condition	SNOMED
intellectual_disability	36717041	Goldberg Shprintzen megacolon syndrome	Condition	SNOMED
intellectual_disability	36676584	14q24.1q24.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	37111328	CAMOS syndrome	Condition	SNOMED
intellectual_disability	35610517	Intellectual development disorder without significant impairment of behaviour	Condition	SNOMED
intellectual_disability	37116294	Spastic paraplegia with precocious puberty syndrome	Condition	SNOMED
intellectual_disability	36716032	GAPO syndrome	Condition	SNOMED
intellectual_disability	35610114	Profound intellectual development disorder without impairment of behaviour	Condition	SNOMED
intellectual_disability	35610121	Severe intellectual development disorder with impairment of behaviour	Condition	SNOMED
intellectual_disability	36714965	Cystic fibrosis with gastritis and megaloblastic anaemia syndrome	Condition	SNOMED
intellectual_disability	35610124	Moderate intellectual development disorder with minimal impairment of behaviour	Condition	SNOMED
intellectual_disability	4334252	Laurence-Moon syndrome	Condition	SNOMED
intellectual_disability	36716144	MEHMO syndrome	Condition	SNOMED
intellectual_disability	36674907	11p15.4 microduplication syndrome	Condition	SNOMED
intellectual_disability	37116389	Pseudoprogeria syndrome	Condition	SNOMED
intellectual_disability	36715405	Short stature with webbed neck and congenital heart disease syndrome	Condition	SNOMED
intellectual_disability	36675060	Polymicrogyria with optic nerve hypoplasia	Condition	SNOMED

intellectual_disability	37118645	Dysmorphism, short stature, deafness, disorder of sex development syndrome	Condition	SNOMED
intellectual_disability	37395832	C syndrome	Condition	SNOMED
intellectual_disability	36674412	Ataxia, photosensitivity, short stature syndrome	Condition	SNOMED
intellectual_disability	35622929	SCN8A-related epilepsy with encephalopathy	Condition	SNOMED
intellectual_disability	36674944	Alopecia, progressive neurological defect, endocrinopathy syndrome	Condition	SNOMED
intellectual_disability	37109594	Isodicentric chromosome 15 syndrome	Condition	SNOMED
intellectual_disability	37311329	Woodhouse Sakati syndrome	Condition	SNOMED
intellectual_disability	36674863	3q27.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	35625463	PURA syndrome	Condition	SNOMED
intellectual_disability	36717093	19q13.11 microdeletion syndrome	Condition	SNOMED
intellectual_disability	36714022	BSG syndrome	Condition	SNOMED
intellectual_disability	35607962	Malan overgrowth syndrome	Condition	SNOMED
intellectual_disability	37203915	Muscle eye brain disease with bilateral multicystic leukodystrophy	Condition	SNOMED
intellectual_disability	36676719	Pitt Hopkins-like syndrome	Condition	SNOMED
intellectual_disability	37204234	Congenital microcephaly, severe encephalopathy, progressive cerebral atrophy syndrome	Condition	SNOMED
intellectual_disability	36715368	Hall Riggs syndrome	Condition	SNOMED
intellectual_disability	4194065	Lowe syndrome	Condition	SNOMED
intellectual_disability	36717192	Juberg Marsidi syndrome	Condition	SNOMED
intellectual_disability	36715415	Deafness, genital anomaly, metacarpal and metatarsal synostosis syndrome	Condition	SNOMED
intellectual_disability	36674869	Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly	Condition	SNOMED
intellectual_disability	36674473	FBLN1-related developmental delay, central nervous system anomaly, syndactyl syndrome	Condition	SNOMED
intellectual_disability	36676515	XYLT1-CDG - xylosyltransferase 1 congenital disorder of glycosylation	Condition	SNOMED
intellectual_disability	4002097	Coffin-Siris syndrome	Condition	SNOMED
intellectual_disability	35622315	Hypotonia, speech impairment, severe cognitive delay syndrome	Condition	SNOMED
intellectual_disability	37118951	Microbrachycephaly, ptosis, cleft lip syndrome	Condition	SNOMED
intellectual_disability	4030676	Prune belly syndrome with pulmonic stenosis, mental retardation and deafness	Condition	SNOMED
intellectual_disability	35622377	Oro-facial digital syndrome type 14	Condition	SNOMED
intellectual_disability	37110069	MOMO syndrome	Condition	SNOMED

intellectual_disability	36674688	Autosomal recessive chorioretinopathy and microcephaly syndrome	Condition	SNOMED
intellectual_disability	35608087	Microcephalus, cerebellar hypoplasia, cardiac conduction defect syndrome	Condition	SNOMED
intellectual_disability	45765465	Partington syndrome	Condition	SNOMED
intellectual_disability	36676501	Roifman syndrome	Condition	SNOMED
intellectual_disability	619073	Mowat-Wilson syndrome due to monosomy 2q22	Condition	SNOMED
intellectual_disability	37396989	L1 syndrome	Condition	SNOMED
intellectual_disability	4121804	Hennekam syndrome	Condition	SNOMED
intellectual_disability	36714637	Temtamy syndrome	Condition	SNOMED
intellectual_disability	36675715	RAB18 deficiency	Condition	SNOMED
intellectual_disability	35622250	Wiedemann Steiner syndrome	Condition	SNOMED
intellectual_disability	37204292	Infantile spasms, psychomotor retardation, progressive brain atrophy, basal ganglia disease syndrome	Condition	SNOMED
intellectual_disability	36674192	2p13.2 microdeletion syndrome	Condition	SNOMED
intellectual_disability	37396247	Karandikar Maria Kamble syndrome	Condition	SNOMED
intellectual_disability	37118677	Microcephalus, glomerulonephritis, marfanoid habitus syndrome	Condition	SNOMED
intellectual_disability	35608131	Diencephalic mesencephalic junction dysplasia	Condition	SNOMED
intellectual_disability	36715334	Fountain syndrome	Condition	SNOMED
intellectual_disability	36714526	Chromosome Xp11.3 microdeletion syndrome	Condition	SNOMED
intellectual_disability	36717348	Schelte syndrome	Condition	SNOMED
intellectual_disability	44783238	Ohdo syndrome, Maat-Kievit-Brunner type	Condition	SNOMED
intellectual_disability	36716153	Oculopalatocerebral syndrome	Condition	SNOMED
intellectual_disability	36715373	Oliver syndrome	Condition	SNOMED
intellectual_disability	36717454	Ectodermal dysplasia with blindness syndrome	Condition	SNOMED
intellectual_disability	36715092	Brachymorphism with onychodysplasia and dysphalangism syndrome	Condition	SNOMED
intellectual_disability	37111018	Bullous dystrophy macular type	Condition	SNOMED
intellectual_disability	37116379	Stimmler syndrome	Condition	SNOMED
intellectual_disability	36716167	Oro-facial digital syndrome type 10	Condition	SNOMED
intellectual_disability	37396271	GMS syndrome	Condition	SNOMED
intellectual_disability	36714054	Pettigrew syndrome	Condition	SNOMED
Post traumatic brain injury	4132546	Traumatic brain injury	Condition	SNOMED
Post traumatic brain injury	4132082	Traumatic brain injury with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4132083	Traumatic brain injury with brief loss of consciousness	Condition	SNOMED

Post traumatic brain injury	4133017	Traumatic brain injury with moderate loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4133018	Traumatic brain injury with prolonged loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4133715	Traumatic brain injury with no loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4182419	Late effect of traumatic injury to brain	Condition	SNOMED
Post traumatic brain injury	46270764	Traumatic brain injury of unknown intent	Condition	SNOMED
Post traumatic brain injury	4001336	Concussion injury of brain	Condition	SNOMED
Post traumatic brain injury	4234112	Brain injury without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	4326435	Post-traumatic epilepsy	Condition	SNOMED
Post traumatic brain injury	443696	Brain stem laceration with open intracranial wound AND no loss of consciousness	Condition	SNOMED
Post traumatic brain injury	36716626	Focal laceration of cerebellum	Condition	SNOMED
Post traumatic brain injury	4193520	Laceration of brain	Condition	SNOMED
Post traumatic brain injury	3655960	Open fracture of vault of skull with cerebral laceration	Condition	SNOMED
Post traumatic brain injury	618758	Cerebral cortex laceration with concussion	Condition	SNOMED
Post traumatic brain injury	618761	Brain stem laceration with concussion	Condition	SNOMED
Post traumatic brain injury	4096615	Cortex laceration and contusion	Condition	SNOMED
Post traumatic brain injury	4167919	Falx laceration	Condition	SNOMED
Post traumatic brain injury	440560	Cerebellar laceration without open intracranial wound AND with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	762826	Post-traumatic epilepsy, refractory	Condition	SNOMED
Post traumatic brain injury	36716576	Multiple focal injuries of cerebellum	Condition	SNOMED
Post traumatic brain injury	443798	Brain stem contusion without open intracranial wound AND with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	375680	Brain stem contusion without open intracranial wound AND with concussion	Condition	SNOMED
Post traumatic brain injury	434190	Cerebellar contusion without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	3655961	Open fracture of vault of skull with cerebral contusion	Condition	SNOMED
Post traumatic brain injury	36716737	Contusion of cerebellum due to birth trauma	Condition	SNOMED
Post traumatic brain injury	432476	Cortex laceration with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	376552	Cerebral laceration and contusion	Condition	SNOMED
Post traumatic brain injury	36716575	Focal laceration of brainstem	Condition	SNOMED

Post traumatic brain injury	4047767	Encephalopathy due to radiation damage	Condition	SNOMED
Post traumatic brain injury	44784521	Post-traumatic dementia with behavioural change	Condition	SNOMED
Post traumatic brain injury	4235306	Repeated concussion	Condition	SNOMED
Post traumatic brain injury	440550	Cortex contusion with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	4034021	Contusion of cerebral cortex	Condition	SNOMED
Post traumatic brain injury	438590	Brain injury with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	3184859	Left temporal lobe contusion	Condition	Nebraska Lexicon
Post traumatic brain injury	618762	Brain stem laceration with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	378264	Open fracture of base of skull with cerebral laceration AND contusion	Condition	SNOMED
Post traumatic brain injury	444379	Cortex laceration with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	42538674	Injury of left visual cortex	Condition	SNOMED
Post traumatic brain injury	4098316	Dissociative convulsions	Condition	SNOMED
Post traumatic brain injury	444217	Brain stem laceration with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	42535731	Dementia following injury caused by exposure to ionizing radiation	Condition	SNOMED
Post traumatic brain injury	4208505	Traumatic cerebral oedema with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	36686191	Contusion of right cerebrum	Condition	SNOMED
Post traumatic brain injury	4048796	Traumatic cerebral oedema	Condition	SNOMED
Post traumatic brain injury	3663250	Contusion of cerebrum with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	434774	Cortex contusion with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	3655953	Contusion of hindbrain	Condition	SNOMED
Post traumatic brain injury	440868	Cortex contusion without open intracranial wound AND with concussion	Condition	SNOMED
Post traumatic brain injury	3186570	Frontal lobe contusion	Condition	Nebraska Lexicon
Post traumatic brain injury	4102446	Spastic paralysis due to intracranial birth injury	Condition	SNOMED
Post traumatic brain injury	4264035	Cerebral compression due to injury	Condition	SNOMED
Post traumatic brain injury	36716577	Focal injury of brainstem	Condition	SNOMED
Post traumatic brain injury	4033376	Hypopituitarism due to radiotherapy	Condition	SNOMED
Post traumatic brain injury	4016975	Hind brain laceration with open intracranial wound, with no loss of consciousness	Condition	SNOMED

Post traumatic brain injury	36715608	Diffuse injury of brainstem	Condition	SNOMED
Post traumatic brain injury	442114	Cortex laceration with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	602945	Necrosis of brain caused by exposure to ionizing radiation	Condition	SNOMED
Post traumatic brain injury	36716603	Radiation injury of brain caused by ionizing radiation following radiotherapy procedure	Condition	SNOMED
Post traumatic brain injury	36715609	Crush injury of brain	Condition	SNOMED
Post traumatic brain injury	4053307	Cerebral decompression injury	Condition	SNOMED
Post traumatic brain injury	4094846	Cerebellar laceration and contusion	Condition	SNOMED
Post traumatic brain injury	4309491	Injuries of brain and cranial nerves with injuries of nerves and spinal cord at neck level	Condition	SNOMED
Post traumatic brain injury	45766193	Hypoxic ischemic encephalopathy due to strangulation	Condition	SNOMED
Post traumatic brain injury	37311964	Focal brain laceration	Condition	SNOMED
Post traumatic brain injury	442762	Cerebellar laceration with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	434792	Cerebellar contusion without open intracranial wound AND with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	37311968	Focal brain contusion	Condition	SNOMED
Post traumatic brain injury	434506	Cerebellar contusion with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	40492393	Concussion injury of cerebrum	Condition	SNOMED
Post traumatic brain injury	4016974	Hind brain laceration with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	442595	Brain stem contusion with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	375671	Concussion with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	36716573	Focal non-haemorrhagic contusion of brainstem	Condition	SNOMED
Post traumatic brain injury	4095993	Laceration of cerebrum	Condition	SNOMED
Post traumatic brain injury	36715607	Diffuse injury of cerebellum	Condition	SNOMED
Post traumatic brain injury	36716568	Focal laceration of cerebrum	Condition	SNOMED
Post traumatic brain injury	4047745	Traumatic encephalopathy	Condition	SNOMED
Post traumatic brain injury	4133019	Cortex laceration	Condition	SNOMED
Post traumatic brain injury	444398	Brain stem laceration without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	4090535	Sunstroke	Condition	SNOMED
Post traumatic brain injury	4096616	Diffuse brain injury	Condition	SNOMED
Post traumatic brain injury	438588	Cortex contusion with open intracranial wound, with no loss of consciousness	Condition	SNOMED

Post traumatic brain injury	442318	Brain stem laceration with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	4046088	Punch drunk syndrome	Condition	SNOMED
Post traumatic brain injury	3655962	Open fracture of skull with cerebral contusion	Condition	SNOMED
Post traumatic brain injury	36686192	Contusion of left cerebrum	Condition	SNOMED
Post traumatic brain injury	36717223	Focal non-haemorrhagic contusion of cerebrum	Condition	SNOMED
Post traumatic brain injury	4094847	Contusion of cerebrum	Condition	SNOMED
Post traumatic brain injury	4096617	Traumatic focal cerebral oedema	Condition	SNOMED
Post traumatic brain injury	44784467	Open fracture of vault of skull with concussion	Condition	SNOMED
Post traumatic brain injury	442280	Brain stem contusion without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	3663252	Contusion of hindbrain with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	4094848	Burst lobe of brain	Condition	SNOMED
Post traumatic brain injury	37311965	Focal contusion of temporal lobe	Condition	SNOMED
Post traumatic brain injury	4154699	Traumatic intracranial subdural hematoma with brief loss of consciousness	Condition	SNOMED
Post traumatic brain injury	44784466	Open fracture of vault of skull with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	37311966	Focal contusion of parietal lobe	Condition	SNOMED
Post traumatic brain injury	441702	Cerebellar contusion with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	435384	Cortex laceration with open intracranial wound, with no loss of consciousness	Condition	SNOMED
Post traumatic brain injury	618760	Cerebellar laceration with concussion	Condition	SNOMED
Post traumatic brain injury	4047907	Self-induced non-photosensitive epilepsy	Condition	SNOMED
Post traumatic brain injury	443799	Brain stem laceration with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	372610	Postconcussion syndrome	Condition	SNOMED
Post traumatic brain injury	4131328	Hypothalamic injury	Condition	SNOMED
Post traumatic brain injury	435953	Cerebellar laceration with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	434197	Cerebellar laceration without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	377439	Visual cortex injury	Condition	SNOMED
Post traumatic brain injury	3655963	Open fracture of skull with cerebral laceration	Condition	SNOMED

Post traumatic brain injury	4208112	Laceration of brain without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	42537144	Injury of both visual cortices	Condition	SNOMED
Post traumatic brain injury	4095994	Traumatic generalized cerebral oedema	Condition	SNOMED
Post traumatic brain injury	440858	Cortex contusion without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	36716540	Injury of brain stem due to birth trauma	Condition	SNOMED
Post traumatic brain injury	4146496	Contusion of brain	Condition	SNOMED
Post traumatic brain injury	378001	Concussion with no loss of consciousness	Condition	SNOMED
Post traumatic brain injury	432751	Cortex contusion with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	373056	Brain injury without open intracranial wound AND with concussion	Condition	SNOMED
Post traumatic brain injury	36716738	Contusion of brain due to birth trauma	Condition	SNOMED
Post traumatic brain injury	4297140	Concussion with mental confusion AND/OR disorientation without loss of consciousness	Condition	SNOMED
Post traumatic brain injury	444248	Brain stem contusion with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	442616	Brain stem contusion with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	604740	Hind brain laceration with open intracranial wound and loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4133716	Cerebellar laceration	Condition	SNOMED
Post traumatic brain injury	36715606	Diffuse injury of cerebrum	Condition	SNOMED
Post traumatic brain injury	440235	Cerebellar laceration with open intracranial wound AND no loss of consciousness	Condition	SNOMED
Post traumatic brain injury	3179550	Cerebral dura mater laceration	Condition	Nebraska Lexicon
Post traumatic brain injury	4072639	Cerebellar decompression injury	Condition	SNOMED
Post traumatic brain injury	435681	Brain injury with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	4347416	Cerebral injury due to birth trauma	Condition	SNOMED
Post traumatic brain injury	439170	Cerebellar contusion with open intracranial wound AND concussion	Condition	SNOMED
Post traumatic brain injury	443931	Cerebellar contusion without open intracranial wound AND with concussion	Condition	SNOMED
Post traumatic brain injury	4236742	Contusion of brain without open intracranial wound	Condition	SNOMED
Post traumatic brain injury	4133020	Cerebellar contusion	Condition	SNOMED

Post traumatic brain injury	4170449	Cerebral trauma	Condition	SNOMED
Post traumatic brain injury	4048139	Cerebral oedema due to birth injury	Condition	SNOMED
Post traumatic brain injury	4016540	Focal brain injury	Condition	SNOMED
Post traumatic brain injury	42538809	Injury of right visual cortex	Condition	SNOMED
Post traumatic brain injury	36716574	Focal traumatic hematoma of brainstem	Condition	SNOMED
Post traumatic brain injury	762827	Post-traumatic epilepsy, non-refractory	Condition	SNOMED
Post traumatic brain injury	444257	Cerebellar laceration with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4038534	Laceration of brain with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	4132548	Brain stem laceration	Condition	SNOMED
Post traumatic brain injury	36716572	Focal traumatic hematoma of cerebellum	Condition	SNOMED
Post traumatic brain injury	36716567	Focal haemorrhagic contusion of cerebrum	Condition	SNOMED
Post traumatic brain injury	4133021	Brain stem contusion	Condition	SNOMED
Post traumatic brain injury	36716570	Focal non-haemorrhagic contusion of cerebellum	Condition	SNOMED
Post traumatic brain injury	440551	Brain injury with open intracranial wound AND loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4019263	Concussion with less than 1 hour loss of consciousness	Condition	SNOMED
Post traumatic brain injury	433342	Cortex contusion without open intracranial wound AND with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	4222768	Contusion of brain with open intracranial wound	Condition	SNOMED
Post traumatic brain injury	36716569	Multiple focal injuries of cerebrum	Condition	SNOMED
Post traumatic brain injury	381978	Brain injury without open intracranial wound AND with loss of consciousness	Condition	SNOMED
Post traumatic brain injury	37311967	Focal contusion of occipital lobe	Condition	SNOMED

Annex II. ENCePP checklist for study protocols

Doc.Ref. EMA/540136/2009

ENCePP Checklist for Study Protocols (Revision 4)

Adopted by the ENCePP Steering Group on 15/10/2018

Study title:

DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

EU PAS Register® number: EUPAS1000000678

Study reference number (if applicable): P4-C2-006

Section 1: Milestones	Yes	No	N/A	Section Number
1.1 Does the protocol specify timelines for				
1.1.1 Start of data collection ¹	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
1.1.2 End of data collection ²	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
1.1.3 Progress report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
1.1.4 Interim report(s)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
1.1.5 Registration in the EU PAS Register®	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
1.1.6 Final report of study results	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	4

Comments:

Section 2: Research question	Yes	No	N/A	Section Number
2.1 Does the formulation of the research question and objectives clearly explain:	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
2.1.1 Why the study is conducted? (e.g. to address an important public health concern, a risk identified in the risk management plan, an emerging safety issue)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	6
2.1.2 The objective(s) of the study?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	7
2.1.3 The target population? (i.e. population or subgroup to whom the study results are intended to be generalised)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5
2.1.4 Which hypothesis(-es) is (are) to be tested?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
2.1.5 If applicable, that there is no <i>a priori</i> hypothesis?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

¹ Date from which information on the first study is first recorded in the study dataset or, in the case of secondary use of data, the date from which data extraction starts.

² Date from which the analytical dataset is completely available.

Comments:

<u>Section 3: Study design</u>	Yes	No	N/A	Section Number
3.1 Is the study design described? (e.g. cohort, case-control, cross-sectional, other design)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.1
3.2 Does the protocol specify whether the study is based on primary, secondary or combined data collection?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
3.3 Does the protocol specify measures of occurrence? (e.g., rate, risk, prevalence)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8
3.4 Does the protocol specify measure(s) of association? (e.g. risk, odds ratio, excess risk, rate ratio, hazard ratio, risk/rate difference, number needed to harm (NNH))	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
3.5 Does the protocol describe the approach for the collection and reporting of adverse events/adverse reactions? (e.g. adverse events that will not be collected in case of primary data collection)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Comments:

<u>Section 4: Source and study populations</u>	Yes	No	N/A	Section Number
4.1 Is the source population described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5
4.2 Is the planned study population defined in terms of:				
4.2.1 Study time period	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.3
4.2.2 Age and sex	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5
4.2.3 Country of origin	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
4.2.4 Disease/indication	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6
4.2.5 Duration of follow-up	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.4
4.3 Does the protocol define how the study population will be sampled from the source population? (e.g. event or inclusion/exclusion criteria)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.5

Comments:

<u>Section 5: Exposure definition and measurement</u>	Yes	No	N/A	Section Number
5.1 Does the protocol describe how the study exposure is defined and measured? (e.g. operational details for defining and categorising exposure, measurement of dose and duration of drug exposure)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6

<u>Section 5: Exposure definition and measurement</u>	Yes	No	N/A	Section Number
5.2 Does the protocol address the validity of the exposure measurement? (e.g. precision, accuracy, use of validation sub-study)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.3 Is exposure categorised according to time windows?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.4 Is intensity of exposure addressed? (e.g. dose, duration)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.5 Is exposure categorised based on biological mechanism of action and taking into account the pharmacokinetics and pharmacodynamics of the drug?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
5.6 Is (are) (an) appropriate comparator(s) identified?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

<u>Section 6: Outcome definition and measurement</u>	Yes	No	N/A	Section Number
6.1 Does the protocol specify the primary and secondary (if applicable) outcome(s) to be investigated?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
6.2 Does the protocol describe how the outcomes are defined and measured?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8
6.3 Does the protocol address the validity of outcome measurement? (e.g. precision, accuracy, sensitivity, specificity, positive predictive value, use of validation sub-study)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
6.4 Does the protocol describe specific outcomes relevant for Health Technology Assessment? (e.g. HRQoL, QALYs, DALYS, health care services utilisation, burden of disease or treatment, compliance, disease management)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

<u>Section 7: Bias</u>	Yes	No	N/A	Section Number
7.1 Does the protocol address ways to measure confounding? (e.g. confounding by indication)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
7.2 Does the protocol address selection bias? (e.g. healthy user/adherer bias)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
7.3 Does the protocol address information bias? (e.g. misclassification of exposure and outcomes, time-related bias)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

Section 8: Effect measure modification	Yes	No	N/A	Section Number
8.1 Does the protocol address effect modifiers? (e.g. collection of data on known effect modifiers, sub-group analyses, anticipated direction of effect)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

Section 9: Data sources	Yes	No	N/A	Section Number
9.1 Does the protocol describe the data source(s) used in the study for the ascertainment of:				
9.1.1 Exposure? (e.g. pharmacy dispensing, general practice prescribing, claims data, self-report, face-to-face interview)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
9.1.2 Outcomes? (e.g. clinical records, laboratory markers or values, claims data, self-report, patient interview including scales and questionnaires, vital statistics)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
9.1.3 Covariates and other characteristics?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	2
9.2 Does the protocol describe the information available from the data source(s) on:				
9.2.1 Exposure? (e.g. date of dispensing, drug quantity, dose, number of days of supply prescription, daily dosage, prescriber)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
9.2.2 Outcomes? (e.g. date of occurrence, multiple events, severity measures related to event)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
9.2.3 Covariates and other characteristics? (e.g. age, sex, clinical and drug use history, co-morbidity, co-medications, lifestyle)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.2
9.3 Is a coding system described for:				
9.3.1 Exposure? (e.g. WHO Drug Dictionary, Anatomical Therapeutic Chemical (ATC) Classification System)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6
9.3.2 Outcomes? (e.g. International Classification of Diseases (ICD), Medical Dictionary for Regulatory Activities (MedDRA))	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
9.3.3 Covariates and other characteristics?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.6
9.4 Is a linkage method between data sources described? (e.g. based on a unique identifier or other)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

Section 10: Analysis plan	Yes	No	N/A	Section Number
10.1 Are the statistical methods and the reason for their choice described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8
10.2 Is study size and/or statistical precision estimated?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

<u>Section 10: Analysis plan</u>	Yes	No	N/A	Section Number
10.3 Are descriptive analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8
10.4 Are stratified analyses included?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8
10.5 Does the plan describe methods for analytic control of confounding?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
10.6 Does the plan describe methods for analytic control of outcome misclassification?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
10.7 Does the plan describe methods for handling missing data?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
10.8 Are relevant sensitivity analyses described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.8

Comments:

<u>Section 11: Data management and quality control</u>	Yes	No	N/A	Section Number
11.1 Does the protocol provide information on data storage? (e.g. software and IT environment, database maintenance and anti-fraud protection, archiving)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
11.2 Are methods of quality assurance described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	10
11.3 Is there a system in place for independent review of study results?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

<u>Section 12: Limitations</u>	Yes	No	N/A	Section Number
12.1 Does the protocol discuss the impact on the study results of:				
12.1.1 Selection bias?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
12.1.2 Information bias?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	11
12.1.3 Residual/unmeasured confounding? (e.g. anticipated direction and magnitude of such biases, validation sub-study, use of validation and external data, analytical methods).	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
12.2 Does the protocol discuss study feasibility? (e.g. study size, anticipated exposure uptake, duration of follow-up in a cohort study, patient recruitment, precision of the estimates)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	8.7

Comments:

<u>Section 13: Ethical/data protection issues</u>	Yes	No	N/A	Section Number
13.1 Have requirements of Ethics Committee/ Institutional Review Board been described?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	13
13.2 Has any outcome of an ethical review procedure been addressed?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
13.3 Have data protection requirements been described?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

<u>Section 14: Amendments and deviations</u>	Yes	No	N/A	Section Number
14.1 Does the protocol include a section to document amendments and deviations?	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

Comments:

<u>Section 15: Plans for communication of study results</u>	Yes	No	N/A	Section Number
15.1 Are plans described for communicating study results (e.g. to regulatory authorities)?	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	14
15.2 Are plans described for disseminating study results externally, including publication?	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	

Comments:

Name of the main author of the protocol: Xintong Li

Date: 13/06/2025

Signature:

